

REFINITIV




# DELTA REPORT

## 10-Q

CARMELL CORP

10-Q - JUNE 30, 2024 COMPARED TO 10-Q - MARCH 31, 2024

The following comparison report has been automatically generated

TOTAL DELTAS	1097
 CHANGES	142
 DELETIONS	312
 ADDITIONS	643

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended **March 31, June 30, 2024**

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-40228

CARMELL CORPORATION

(Exact Name of Registrant as Specified in its Charter)

Delaware

( State or other jurisdiction of  
incorporation or organization)

2403 Sidney Street, Suite 300

Pittsburgh, Pennsylvania

(Address of principal executive offices)

86-1645738

(I.R.S. Employer  
Identification No.)

15203

(Zip Code)

Registrant's telephone number, including area code: (919) 313-9633

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.0001 per share	CTCX	The Nasdaq Stock Market LLC
Redeemable Warrants, each whole warrant exercisable for one share of		
Common Stock at an exercise price of \$11.50	CTCXW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer   
 Non-accelerated filer   
 Emerging growth company

Accelerated filer   
 Smaller reporting company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of **May 10, 2024** **August 11, 2024**, the registrant had **20,803,228** **20,905,407** shares of common stock, \$0.0001 par value per share, outstanding.

## Table of Contents

		Page
<b>PART I.</b>	<b>FINANCIAL INFORMATION</b>	
Item 1.	<a href="#">Unaudited Condensed Consolidated Financial Statements</a>	
	<a href="#">Condensed Consolidated Balance Sheets</a>	1
	<a href="#">Condensed Consolidated Statements of Operations</a>	2
	<a href="#">Condensed Consolidated Statements of Stockholders' Deficit</a>	3
	<a href="#">Condensed Consolidated Statements of Cash Flows</a>	4
	<a href="#">Notes to Unaudited Condensed Consolidated Financial Statements</a>	5 6
Item 2.	<a href="#">Management's Discussion and Analysis of Financial Condition and Results of Operations</a>	25 26
Item 3.	<a href="#">Quantitative and Qualitative Disclosures About Market Risk</a>	29 32
Item 4.	<a href="#">Controls and Procedures</a>	29 32
<b>PART II.</b>	<b>OTHER INFORMATION</b>	
Item 1.	<a href="#">Legal Proceedings</a>	30 33
Item 1A.	<a href="#">Risk Factors</a>	30 33
Item 2.	<a href="#">Unregistered Sales of Equity Securities and Use of Proceeds</a>	30 33
Item 3.	<a href="#">Defaults Upon Senior Securities</a>	30 33
Item 4.	<a href="#">Mine Safety Disclosures</a>	30 33
Item 5.	<a href="#">Other Information</a>	30 33
Item 6.	<a href="#">Exhibits</a>	31 35
	<a href="#">Signatures</a>	32 36

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

**CARMELL CORPORATION**  
CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31, 2024 (unaudited)	December 31, 2023	June 30, 2024 (unaudited)	December 31, 2023
<b>ASSETS</b>				
<b>Current assets:</b>				
Cash	\$ 892,161	\$ 2,912,461	\$ 2,198,275	\$ 2,912,461
Prepaid expenses	531,327	761,271	164,163	761,271
Forward purchase agreement	3,543,614	5,700,451	1,420,137	5,700,451
Inventory	113,872	—		
Income taxes receivable	204,559	204,559		
Assets available for sale	—	53,321,372	—	53,321,372
Income taxes receivable	204,559	204,559		
Other current assets	17,563	—		
<b>Total current assets</b>	<b>5,189,224</b>	<b>62,900,114</b>	<b>4,101,006</b>	<b>62,900,114</b>
Property and equipment, net of accumulated depreciation of \$645,114 and \$622,714, respectively	170,447	192,846		
Property and equipment, net of accumulated depreciation of \$667,512 and \$622,714, respectively	148,049	192,846		
Operating lease right of use asset	797,617	831,656	762,877	831,656
Intangible assets, net of accumulated amortization of \$47,691 and \$46,559, respectively	23,055	24,187		
Intangible assets, net of accumulated amortization of \$48,823 and \$46,559, respectively	21,923	24,187		
<b>Total assets</b>	<b>\$ 6,180,343</b>	<b>\$ 63,948,803</b>	<b>\$ 5,033,855</b>	<b>\$ 63,948,803</b>
<b>LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY</b>				
<b>Current liabilities:</b>				
Accounts payable	\$ 4,283,470	\$ 4,417,234	\$ 4,095,418	\$ 4,417,234
Accrued interest	1,175,845	1,175,845	1,175,845	1,175,845
Accrued expenses and other liabilities	568,345	1,595,434	335,626	1,595,434
Loans payable, net of debt discount	731,340	1,288,598	21,286	1,288,598
Operating lease liability	146,552	150,136	149,503	150,136
Liabilities available for sale	—	29,874,831	—	29,874,831
<b>Total current liabilities</b>	<b>6,905,552</b>	<b>38,502,078</b>	<b>5,777,678</b>	<b>38,502,078</b>
<b>Long-term liabilities:</b>				
Operating lease liability, net of current portion	666,450	697,715	627,949	697,715

<b>Total liabilities</b>	<b>7,572,002</b>	<b>39,199,793</b>	<b>6,405,627</b>	<b>39,199,793</b>
<b>Commitments and contingencies (see Note 10)</b>				
<b>Commitments and contingencies (see Note 9)</b>				
<b>Stockholders' (deficit) equity:</b>				
Series A convertible voting preferred stock, \$0.0001 par value; -0- and 4,243 shares authorized, issued and outstanding at March 31, 2024, and December 31, 2023, respectively	—	1		
Common stock, \$0.0001 par value, 250,000,000 shares authorized, and 19,361,068 and 23,090,585 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	1,936	2,309		
Series A convertible voting preferred stock, \$0.0001 par value; -0- and 4,243 shares authorized, issued and outstanding at June 30, 2024 and December 31, 2023, respectively	—	1		
Common stock, \$0.0001 par value, 250,000,000 shares authorized, and 20,905,407 and 23,090,585 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively	2,091	2,309		
Additional paid-in capital	60,380,765	83,250,101	63,705,035	83,250,101
Accumulated deficit	(61,774,360)	(58,503,401)	(65,078,898)	(58,503,401)
<b>Total stockholders' (deficit) equity</b>	<b>(1,391,659)</b>	<b>24,749,010</b>	<b>(1,371,772)</b>	<b>24,749,010</b>
<b>Total liabilities and stockholders' (deficit) equity</b>	<b>\$ 6,180,343</b>	<b>\$ 63,948,803</b>	<b>\$ 5,033,855</b>	<b>\$ 63,948,803</b>

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

1

**CARMELL CORPORATION**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  
(Unaudited)

	For the Three Months Ended		For the Three Months Ended		For the Six Months Ended	
	March 31,		June 30,		June 30,	
	2024	2023	2024	2023	2024	2023
Revenue, net of discounts	\$ 12,320	\$ —	\$ 12,320	\$ —		
Cost of Goods Sold	292	—	292	—		
Gross Profit	12,028	—	12,028	—		
Operating expenses:						
Selling and marketing	11,045	—	11,045	—		
Research and development	\$ 429,420	\$ 740,325	104,066	823,657	533,486	1,563,982
General and administrative	927,394	510,445	1,064,874	637,453	1,992,268	1,147,898

Depreciation and amortization of intangible assets	23,531	24,101	23,530	26,274	47,061	50,375
Restructuring charges	—	—				
Total operating expenses	1,380,345	1,274,871	1,203,515	1,487,384	2,583,860	2,762,255
<b>Loss from operations</b>	<b>(1,380,345)</b>	<b>(1,274,871)</b>	<b>(1,191,487)</b>	<b>(1,487,384)</b>	<b>(2,571,832)</b>	<b>(2,762,255)</b>
Other income (expense):						
Other income	9,054	34,541				
Other income (expense)	19,771	(461)	28,825	34,080		
Interest expense	(11,566)	(262,597)	(3,264)	(268,437)	(14,830)	(531,034)
Amortization of debt discount	(13,468)	(703)	(6,081)	(7,597)	(19,549)	(8,300)
Loss on forward purchase agreement	(2,156,837)	—	(2,123,477)	—	(4,280,314)	—
Change in fair value of derivative liabilities	—	(325,085)	—	(3,545,073)	—	(3,870,158)
Loss on debt extinguishment	—	—				
Total other income (expense)	(2,172,817)	(553,844)	(2,113,051)	(3,821,568)	(4,285,868)	(4,375,412)
<b>Loss from continuing operations before provision for income taxes</b>	<b>(3,553,162)</b>	<b>(1,828,715)</b>	<b>(3,304,538)</b>	<b>(5,308,952)</b>	<b>(6,857,700)</b>	<b>(7,137,667)</b>
Provision for income taxes	—	—	—	—	—	—
<b>Loss from continuing operations</b>	<b>(3,553,162)</b>	<b>(1,828,715)</b>	<b>(3,304,538)</b>	<b>(5,308,952)</b>	<b>(6,857,700)</b>	<b>(7,137,667)</b>
Loss from discontinued operations attributable to common shareholders	(1,252,276)	—	—	—	(1,252,276)	—
Gain on sale of discontinued operations attributable to common shareholders	1,534,479	—	—	—	1,534,479	—
<b>Net loss</b>	<b>(3,270,959)</b>	<b>(1,828,715)</b>	<b>(3,304,538)</b>	<b>(5,308,952)</b>	<b>(6,575,497)</b>	<b>(7,137,667)</b>
Dividends on Legacy Series A, Legacy Series C-1, and Legacy C-2 preferred stock	—	(311,168)	—	(315,477)	—	(626,645)
<b>Net loss attributable to common stockholders</b>	<b>\$ (3,270,959)</b>	<b>\$ (2,139,883)</b>	<b>\$ (3,304,538)</b>	<b>\$ (5,624,429)</b>	<b>\$ (6,575,497)</b>	<b>\$ (7,764,312)</b>
<b>Net (loss) income per common share - basic and diluted:</b>						
Net loss from continuing operations	\$ (0.16)	\$ (1.91)	\$ (0.16)	\$ (5.00)	\$ (0.31)	\$ (6.89)
Discontinued operations, net of tax	0.02	—	—	—	0.01	—
<b>Net loss per common share</b>	<b>\$ (0.14)</b>	<b>\$ (1.91)</b>	<b>\$ (0.16)</b>	<b>\$ (5.00)</b>	<b>\$ (0.30)</b>	<b>\$ (6.89)</b>
Weighted average of common shares outstanding - basic and diluted	22,915,160	1,122,529	20,735,019	1,124,601	21,825,089	1,126,673

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

## CARMELL CORPORATION

### CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)

For the Three and Six Months Ended **March 31, 2024** **June 30, 2024** and 2023

(Unaudited)

	Series A		Common Stock		Additional		Series A			
	Preferred Stock		Common Stock		Paid-in	Accumulated	Preferred Stock	Common Stock	Paid-in	Accumulated
	Shares	Amount	Shares	Amount	Capital	Deficit	Total			
<b>Balance at</b>										
<b>March 31,</b>										
<b>2024</b>	—	\$ —	19,361,068	\$ 1,936	\$ 60,380,765	\$ (61,774,360)	\$ (1,391,659)			
Common										
Stock issued										
in connection										
with										
Promissory										
Notes	—	—	212,887	21	473,479	—	473,500			
Common										
Stock issued	—	—	1,331,452	134	2,687,091	—	2,687,225			
Stock-based										
compensation										
expense	—	—	—	—	163,700	—	163,700			
Net loss	—	—	—	—	—	(3,304,538)	(3,304,538)			
<b>Balance at</b>										
<b>June 30,</b>										
<b>2024</b>	—	\$ —	<b>20,905,407</b>	<b>\$ 2,091</b>	<b>\$ 63,705,035</b>	<b>\$ (65,078,898)</b>	<b>\$ (1,371,772)</b>			
<b>Balance at</b>										
<b>March 31,</b>										
<b>2023</b>	—	\$ —	896,580	\$ 897	\$ 4,777,476	\$ (44,522,174)	\$ (39,743,801)			
Accrued										
Legacy										
Series A										
preferred										
stock										
dividend	—	—	—	—	—	(76,771)	(76,771)			
Accrued										
Legacy										
Series C-1										
preferred										
stock										
dividend	—	—	—	—	—	(18,923)	(18,923)			

Accrued Legacy Series C-2 preferred stock dividend	—	—	—	—	—	(219,783)	(219,783)
Exercise of common stock warrants	—	—	14,478	1	25,877	—	25,878
Warrants issued in connection with Promissory Notes	—	—	—	—	48,950	—	48,950
Stock-based compensation expense	—	—	—	—	187,030	—	187,030
Net loss	—	—	—	—	—	(5,308,952)	(5,308,952)
<b>Balance at June 30, 2023</b>	<b>—</b>	<b>\$ —</b>	<b>911,058</b>	<b>\$ 898</b>	<b>\$ 5,039,333</b>	<b>\$ (50,146,603)</b>	<b>\$ (45,106,372)</b>
<b>Balance at January 1, 2024</b>	<b>4,243</b>	<b>\$ 1</b>	<b>23,090,585</b>	<b>\$ 2,309</b>	<b>\$ 83,250,101</b>	<b>\$ (58,503,401)</b>	<b>\$ 24,749,010</b>
Stock received from AxoBio Disposition	(4,243)	(1)	(3,845,337)	(385)	(23,455,793)	—	(23,456,179)
Common Stock issued in connection with Promissory Notes	—	—	328,707	33	848,467	—	848,500
Common Stock issued	—	—	1,331,452	134	2,687,091	—	2,687,225
Stock-based compensation expense	—	—	—	—	375,169	—	375,169
Net loss	—	—	—	—	—	(6,575,497)	(6,575,497)
<b>Balance at June 30, 2024</b>	<b>—</b>	<b>\$ —</b>	<b>20,905,407</b>	<b>\$ 2,091</b>	<b>\$ 63,705,035</b>	<b>\$ (65,078,898)</b>	<b>\$ (1,371,772)</b>
	<b>Shares</b>	<b>Amount</b>	<b>Shares</b>	<b>Amount</b>	<b>Capital</b>	<b>Deficit</b>	<b>Total</b>

<b>Balance at January 1, 2023</b>	—	\$	—	896,580	\$	897	\$	4,590,855	\$	(42,382,291)	\$	(37,790,539)	—	\$	—	896,580	\$	897	\$	4,590,855	\$	(42,382,291)	\$	(37,790,539)
Accrued Legacy Series A preferred stock dividends	—	—	—	—	—	—	—	—	(75,084)	(75,084)	—	—	—	—	—	—	—	—	—	—	—	(151,855)	(151,855)	
Accrued Legacy Series C-1 preferred stock dividends	—	—	—	—	—	—	—	—	(18,716)	(18,716)	—	—	—	—	—	—	—	—	—	—	—	(37,639)	(37,639)	
Accrued Legacy Series C-2 preferred stock dividends	—	—	—	—	—	—	—	—	(217,368)	(217,368)	—	—	—	—	—	—	—	—	—	—	—	(437,151)	(437,151)	
Exercise of common stock options	—	—	14,478	1	25,877					25,878														
Warrants issued in connection with Promissory Notes	—	—	—	—	6,112				6,112					55,062								—	55,062	
Stock-based compensation expense	—	—	—	—	180,509				180,509					367,539								—	367,539	
Net loss	—	—	—	—	—				(1,828,715)	(1,828,715)	—	—	—	—	—	—	—	—	—	—	—	(7,137,667)	(7,137,667)	
<b>Balance at March 31, 2023</b>	—	\$	—	896,580	\$	897	\$	4,777,476	\$	(44,522,174)	\$	(39,743,801)												
<b>Balance at January 1, 2024</b>	4,243	\$	1	23,090,585	\$	2,309	\$	83,250,101	\$	(58,503,401)	\$	24,749,010												
Common Stock issued in connection with conversion of Promissory Notes	—	—	115,820	12	374,988				—	375,000														

Stock received from AxoBio							
Disposition	(4,243)	(1)	(3,845,337)	(385)	(23,455,793)	—	(23,456,179)
Stock-based compensation expense	—	—	—	—	211,469	—	211,469
Net loss	—	—	—	—	—	(3,270,959)	(3,270,959)
<b>Balance at March 31, 2024</b>	<b>—</b>	<b>\$ -</b>	<b>19,361,068</b>	<b>\$ 1,936</b>	<b>\$ 60,380,765</b>	<b>\$ (61,774,360)</b>	<b>\$ (1,391,659)</b>
<b>Balance at June 30, 2023</b>	<b>—</b>	<b>\$ —</b>	<b>911,058</b>	<b>\$ 898</b>	<b>\$ 5,039,333</b>	<b>\$ (50,146,603)</b>	<b>\$ (45,106,372)</b>

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

**CARMELL CORPORATION**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(Unaudited)

	For the Three Months Ended March 31,		For the Six Months Ended June 30,	
	2024	2023	2024	2023
<b>Cash flows from operating activities:</b>				
Net loss from continuing operations	\$ (3,553,162)	\$ (1,828,715)	\$ (6,857,700)	\$ (7,137,667)
Loss from discontinued operations, net of tax	(1,252,276)	—	(1,252,276)	—
Gain on sale of discontinued operations	1,534,479	—	1,534,479	—
Adjustments to reconcile net loss to net cash used in operating activities:				
Gain on sale of discontinued operations	(1,534,479)	—	(1,534,479)	—
Stock-based compensation	211,469	180,509	375,169	367,539
Depreciation and amortization of intangible assets	23,531	24,101	47,061	50,375
Amortization of right of use assets	34,039	35,809	68,779	71,621
Amortization of debt discount	13,468	703	19,549	8,300
Change in fair value of forward purchase agreement	2,156,837	—	4,280,314	—
Change in fair value of derivative liabilities	—	325,085	—	3,870,158
Changes in operating assets and liabilities:				
Prepaid expenses	229,944	47,826	597,108	49,603
Inventory	(113,872)	—	—	—
Assets available for sale	4,662,980	—	4,662,980	—
Other current assets	(17,563)	11,183	—	28,175

Accounts payable	(133,764)	159,097	(321,816)	599,520
Accrued expenses and other liabilities	(1,027,089)	337,258	(1,259,808)	668,664
Lease liability	(34,849)	(31,413)	(70,399)	(63,460)
Accrued interest	—	262,598	—	531,035
Liabilities available for sale	(2,389,343)	—	(2,389,343)	—
<b>Net cash used in operating activities</b>	<b>(1,075,778)</b>	<b>(475,959)</b>	<b>(2,214,254)</b>	<b>(956,137)</b>
<b>Cash flows from investing activities</b>				
Cash paid in AxoBio Disposition	(748,796)	—	(748,796)	—
Purchase of property and equipment	—	(30,470)		
<b>Net cash used in investing activities</b>	<b>(748,796)</b>	<b>—</b>	<b>(748,796)</b>	<b>(30,470)</b>
<b>Cash flows from financing activities:</b>				
Proceeds from issuance of loans and related warrants	31,538	375,000		
Proceeds from issuance of Common Stock, net of costs	2,687,225	—		
Proceeds from issuance of loans	31,538	848,500		
Payment of loans	(227,264)	—	(469,899)	—
<b>Net cash (used in) provided by financing activities</b>	<b>(195,726)</b>	<b>375,000</b>		
Proceeds from common stock option exercises	—	25,878		
<b>Net cash provided by financing activities</b>	<b>2,248,864</b>	<b>874,378</b>		
<b>Net decrease in cash</b>	<b>(2,020,300)</b>	<b>(100,959)</b>	<b>(714,186)</b>	<b>(112,229)</b>
Cash - beginning of the period	2,912,461	128,149	2,912,461	128,149
<b>Cash - end of the period</b>	<b>\$ 892,161</b>	<b>\$ 27,190</b>	<b>\$ 2,198,275</b>	<b>\$ 15,920</b>
<b>Supplemental cash flow information:</b>				
Interest paid	\$ 11,566	\$ 37,037	\$ 14,830	\$ —
Income taxes paid	—	—	—	—
<b>Non-cash financing activity:</b>				
Net assets sold in AxoBio Acquisition	\$ 21,921,697	\$ —		
Fair value of shares received in AxoBio Disposition	23,456,179	—		
Common Stock issued in connection with conversion of Promissory Notes	375,000	—		
Accrued Legacy Series A preferred stock dividends	—	75,084		
Accrued Legacy Series C-1 preferred stock dividends	—	18,716		
Accrued Legacy Series C-2 preferred stock dividends	—	217,368		
Warrants issued in connection with convertible notes	—	6,112		
Unpaid deferred offering costs	—	660,426		

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

## CARMELL CORPORATION

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued)****(Unaudited)**

	For the Six Months Ended June 30,	
	2024	2023
<b>Non-cash financing activity:</b>		
Net assets sold in AxoBio Acquisition	\$ 21,921,697	\$ —
Fair value of shares received in AxoBio Disposition	23,456,179	—
Common Stock issued in connection with conversion of Promissory Notes	848,500	—
Accrued Legacy Series A preferred stock dividends	—	151,855
Accrued Legacy Series C-1 preferred stock dividends	—	37,639
Accrued Legacy Series C-2 preferred stock dividends	—	437,151
Warrants issued in connection with promissory notes	—	55,062
Unpaid deferred offering costs	—	923,222

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

45

**CARMELL CORPORATION****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****(Unaudited)****NOTE 1 — NATURE OF THE ORGANIZATION AND BUSINESS**

Unless the context requires otherwise, references to “Carmell,” or the “Company” prior to the closing of the Business Combination (as defined below), are intended to refer to Carmell Therapeutics Corporation, a Delaware corporation, (“Legacy Carmell”), and, after the closing of the Business Combination, are intended to refer to Carmell Corporation, a Delaware corporation, and its consolidated subsidiaries.

Carmell Corporation is a bio-aesthetics company developing cosmetic skincare and haircare products that utilize the **human platelet secretome Carmell Secretome™** to topically deliver proteins and growth factors to support skin and hair health. **The Carmell Secretome™ consists of a potent cocktail of proteins, peptides and bio-lipids extracted from allogeneic human platelets sourced from U.S. Food and Drug Administration-approved tissue banks.** The Company’s product pipeline also includes innovative bone and wound healing products that are under development. Carmell’s operations are based in Pittsburgh, Pennsylvania. The Company operates as a single segment, and all of its operations are located in the United States. Carmell’s common stock, par value \$0.0001 per share (the “Common Stock”), and Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of \$11.50 (the “Public Warrants”), trade on The Nasdaq Capital Market under the ticker symbols “CTCX” and “CTCXW”, respectively.

*Business Combination*

On July 14, 2023 (the “Closing Date”), the Company consummated a business combination (the “Business Combination”) pursuant to the terms of the Business Combination Agreement, dated as of January 4, 2023 (the “Business Combination Agreement”), by and among Alpha Healthcare Acquisition Corp. III, a Delaware corporation and the predecessor of Carmell (“Alpha”), Candy Merger Sub, Inc., a Delaware corporation (“Merger Sub”) and Legacy Carmell, pursuant to which Merger Sub merged with and into Legacy Carmell, with Legacy Carmell as the surviving company of the Business Combination. After giving effect to the Business Combination, Legacy Carmell became a wholly owned subsidiary of the Company. Pursuant to the Business Combination Agreement, on the Closing Date, Alpha changed its name to “Carmell Therapeutics Corporation” and Legacy Carmell changed its name to “Carmell Regen Med Corporation.” On August 1, 2023, the Company filed an amendment to its Third Amended and Restated Certificate of Incorporation with the Delaware Secretary of State to change its name to “Carmell Corporation.”

Pursuant to the Business Combination Agreement, at the effective time of the Business Combination (the "Effective Time"), (i) each outstanding share of common stock of Legacy Carmell (the "Legacy Carmell common stock") was converted into the right to receive a number of shares of Common Stock equal to the applicable Exchange Ratio (as defined below in the Business Combination Agreement); (ii) each outstanding share of preferred stock of Legacy Carmell was converted into the right to receive the aggregate number of shares of Common Stock that would be issued upon conversion of the underlying Legacy Carmell common stock, multiplied by the applicable Exchange Ratio; (iii) each outstanding option and warrant to purchase Legacy Carmell common stock was converted into an option or warrant, as applicable, to purchase a number of shares of Common Stock equal to the number of shares of Legacy Carmell common stock subject to such option or warrant multiplied by the applicable Exchange Ratio; and (iv) each outstanding share of Alpha Class A common stock, par value \$0.0001 per share ("Class A Common Stock"), and each share of Alpha Class B common stock, par value \$0.0001 per share ("Class B Common Stock"), was converted into one share of Common Stock. As of the Closing Date, the Exchange Ratio with respect to Legacy Carmell common stock was 0.06154, and the Exchange Ratio with respect to each outstanding derivative equity security of Legacy Carmell was between 0.06684 and 0.10070.

On July 11, 2023, the record date for the special meeting of Alpha's stockholders to approve the Business Combination (the "Special Meeting"), there were (i) 15,444,103 shares of Class A Common Stock issued and outstanding and (ii) 3,861,026 shares of Class B Common Stock issued and outstanding and held by AHAC Sponsor III LLC, Alpha's sponsor (the "Sponsor"). In addition, on the closing date of Alpha's initial public offering (the "IPO"), Alpha had issued 455,000 warrants to purchase Class A Common Stock to the Sponsor in a private placement. Prior to the Special Meeting, holders of 12,586,223 shares of Alpha Class A Common Stock included in the units issued in Alpha's IPO (excluding 1,705,959 shares of the Class A Common Stock purchased by Meteora (as defined below) directly from the redeeming stockholders under the Forward Purchase Agreement (as defined below)) exercised their right to redeem such shares for cash at a price of approximately \$10.28 per share (net of the withholding for federal and franchise tax liabilities), for an aggregate redemption price of approximately \$29,374,372. The redemption price was paid out of Alpha's trust account, which, after taking into account the redemptions but before any transaction expense, had a balance of \$29,376,282 at the Closing Date.

The Business Combination was accounted for as a reverse recapitalization in accordance with accounting principles generally accepted in the United States ("GAAP"), and under . Under this method of accounting, Alpha was treated as the acquired company for financial reporting purposes, and Legacy Carmell was treated as the accounting acquirer. Operations prior to the Business Combination are those of Legacy

56

---

Carmell. Unless otherwise noted, the Company has retroactively adjusted all common and preferred share and related share price information to give effect to the Exchange Ratio established in the Business Combination Agreement.

#### *Axolotl Biologix Acquisition*

On August 9, 2023 (the "Merger Closing Date"), the Company completed the acquisition of Axolotl Biologix, Inc. ("AxoBio") pursuant to an Agreement and Plan of Merger, dated July 26, 2023 (as amended, the "Merger Agreement"), by and among the Company, AxoBio, Aztec Merger Sub, Inc., a wholly owned subsidiary of the Company ("Merger Sub I"), and Axolotl Biologix LLC, a wholly owned subsidiary of the Company ("Merger Sub II"). Upon the closing of the transactions contemplated by the Merger Agreement, (a) Merger Sub I merged with and into AxoBio, after which the separate corporate existence of Merger Sub I ceased, and AxoBio continued as the surviving corporation, and (b) AxoBio merged with and into Merger Sub II, after which AxoBio ceased to exist, and Merger Sub II survived as a wholly owned subsidiary of the Company (collectively, the "AxoBio Acquisition"). At the effective time of the AxoBio Acquisition (the "Merger Effective Time"), each share of AxoBio's common stock, par value \$0.001 per share, (other than Dissenting Shares (as defined in the Merger Agreement) and shares held as treasury stock) issued and outstanding as of immediately prior to the Merger Effective Time was canceled and converted into the right to receive a pro rata share of:

- \$8,000,000 in cash (the "Closing Cash Consideration"), payable upon delivery of AxoBio's audited financial statements;
- 3,845,337 shares of Common Stock and 4,243 shares of a newly designated series of Series A Convertible Voting Preferred Stock (the "Series A Preferred Stock") issued upon the Merger Closing Date (the "Closing Share Consideration"); and
- up to \$9,000,000 in cash and up to \$66,000,000 in shares of Common Stock that, in each case, were subject to the achievement of certain revenue targets and research and development milestones (the "Earnout").

#### *Axolotl Biologix Disposition*

On March 20, 2024, the Company entered into a Membership Interest Purchase Agreement (the "Purchase Agreement") with the former stockholders of AxoBio, including Burns Ventures, LLC, a Texas limited liability company ("BVLLC"), H. Rodney Burns, an individual resident of Texas ("Burns"), AXO XP, LLC, an Arizona limited liability company ("AXPLLC"), and Protein Genomics, LLC, a Delaware corporation ("PGEN" and together with BVLLC, Burns, and AXPLLC, collectively, the "Buyers" and each, a "Buyer"), providing for, upon the terms and subject to the conditions set forth therein, the sale by the Company of all outstanding limited liability company interests of AxoBio (the "AxoBio Disposition") to the Buyers for aggregate consideration as described below. The AxoBio Disposition closed on March 26, 2024.

The consideration for the AxoBio Disposition consisted of (i) the Closing Share Consideration, initially issued as consideration to the Buyers under the Merger Agreement, (ii) cancellation of the notes payable to the Buyers in an aggregate principal amount of \$8,000,000 issued as the Closing Cash Consideration in the AxoBio Acquisition and (iii) termination of the Company's obligations with respect to the Earnout.

#### *Risks and Uncertainties*

Disruption of global financial markets and a recession or market correction, including the ongoing military conflicts between Russia and Ukraine and the related sanctions imposed against Russia, as well as the conflict between Israel and Hamas and the related tensions in the Middle East and other global macroeconomic factors such as inflation and changes in interest rates, could reduce the Company's ability to access capital, which could in the future negatively affect the Company's liquidity and could materially affect the Company's business and the value of its Common Stock.

## **NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

#### *Basis of Presentation*

The unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The accompanying unaudited condensed consolidated financial statements include all adjustments that are of a normal recurring nature and necessary for the fair presentation of the results for the interim periods presented. Results for interim periods are not necessarily indicative of results to be expected for the full year.

#### *Emerging Growth Company Status*

The Company is an "emerging growth company," as defined in Section 2(a) of the Securities Act of 1933, as amended (the "Securities Act"), as modified by the Jumpstart our Business Startups Act of 2012 (the "JOBS Act"), and it may take advantage of certain

7

---

exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the "Exchange Act")), are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies, but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make a comparison of the Company's financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

#### *Use of Estimates*

The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. Significant estimates in these unaudited condensed consolidated financial statements include those related to the forward purchase asset, earnout liabilities, derivative liabilities, long-term assets and goodwill impairment, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets, and contingent liabilities. If the underlying estimates and assumptions upon which the unaudited condensed consolidated financial statements are based change in the future, actual amounts may differ from those included in the accompanying unaudited condensed consolidated financial statements.

#### *Business Combinations*

The Company allocates the fair value of the purchase consideration of its acquisitions to the tangible assets, liabilities, and intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Acquisition-related expenses are expensed as incurred and included in general and administrative expenses.

The allocation of the purchase price requires management to make significant estimates in determining the fair values of assets acquired and liabilities assumed, especially with respect to intangible assets. These estimates are based on information obtained from management of the acquired companies and historical experience. These estimates can include, but are not limited to, the cash flows that an asset is expected to generate in the future and the cost savings expected to be derived from acquiring an asset. These estimates are inherently uncertain and unpredictable, and if different estimates were used, the purchase price for the acquisition could be allocated to the acquired assets and liabilities differently from the allocation that the Company has made.

#### *Discontinued Operations*

On March 26, 2024, the Company completed the AxoBio Disposition as described in Note 1 above. In accordance with Financial Accounting Standards Board Accounting Standards Codification ("ASC") 205, *Presentation of Financial Statements, Discontinued Operations, Other Presentation Matters* ("ASC 205"), the assets and liabilities of AxoBio are classified as available for sale on the accompanying unaudited condensed consolidated balance sheets, and the results of its operations are reported as discontinued operations in the accompanying unaudited condensed consolidated statements of operations.

#### *Segment Reporting*

ASC Topic No. 280, *Segment Reporting* ("ASC 280"), establishes standards for the way that public business enterprises report information about operating segments in their annual consolidated financial statements and requires that those enterprises report selected information about operating segments in interim financial reports. ASC 280 also establishes standards for related disclosures about products and services, geographic areas and major customers. The Company's business segments are based on the organizational structure used by the chief operating decision maker to make operating and investment decisions and assess performance. Our chief executive officer, who is our chief operating decision maker, views the Company's operations and manages its business in one operating segment, which is the business of developing and commercializing cosmetic and regenerative care products.

#### *Cash and Cash Equivalents*

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash

---

equivalents. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company's cash and cash equivalents balance exceeds the federally insured limits, which potentially subject the Company to concentrations of credit risk. For the six months ended June 30, 2024 and 2023, the Company has experienced no losses related to its cash and cash equivalents that exceed federally insured deposit limits. As of June 30, 2024, the Company had cash in excess of federally insured limits of \$1,833,647. As of June 30, 2024 and December 31, 2023, the Company had cash equivalents of \$25,191 and \$30,000, respectively. Cash equivalents as of December 31, 2023 are classified as a component of assets available for sale in the accompanying unaudited condensed consolidated balance sheets.

#### *Forward Purchase Agreement*

On July 9, 2023, Alpha and each of Meteora Special Opportunity Fund I, LP ("MSOF"), Meteora Capital Partners, LP ("MCP") and Meteora Select Trading Opportunities Master, LP ("MSTO") (with and together with MCP, MSOF, and MSTO collectively as MSOF, the "Sellers" or "Meteora") entered into a forward purchase agreement (the "Forward Purchase Agreement") providing for an over-the-counter equity forward transaction relating to, prior to the Effective Time, the

Class A Common Stock and, after the Effective Time, the Common Stock. Pursuant to the terms of the Forward Purchase Agreement, at the closing of the Business Combination, Closing Date, the Sellers purchased directly from the stockholders of Alpha 1,705,959 shares of Class A Common Stock (the "Recycled Shares") at a price of \$10.28 per share (the "Initial Price"), which is the price equal to the redemption price at which holders of Class A Common Stock were permitted to redeem their shares in connection with the Business Combination pursuant to Section 9.2(a) of Alpha's Second Amended and Restated Certificate of Incorporation, as amended (the "Second Amended Charter").

In accordance with the terms of the Forward Purchase Agreement, at the Closing Date, the Company paid to the Sellers an aggregate cash amount of \$17,535,632, which was equal to the product of (a) the Recycled Shares and (b) the Initial Price. The settlement date will be the earliest to occur of (a) the first anniversary of the Closing Date and (b) after the occurrence of (i) a Delisting Event (as defined in the Forward Purchase Agreement) or (ii) a Registration Failure (as defined in the Forward Purchase Agreement), upon the date specified by Meteora in a written notice delivered to the Company at Meteora's discretion (which settlement date shall not be earlier than the date of such notice). Any Recycled Shares not sold in accordance with the early termination provisions described below will incur a \$0.50 per share termination fee payable by the Company to Meteora at settlement.

From time to time and on any date following the Business Combination (any such date, an "OET Date") and subject to the terms and conditions below, Meteora may, in its absolute discretion, and so long as the daily volume-weighted average price ("VWAP Price") of the Recycled Shares is equal to or exceeds the Reset Price (as defined in the Forward Purchase Agreement), terminate the transaction in whole or in part by providing written notice (an "OET Notice") in accordance with the terms of the Forward Purchase Agreement. The effect of an OET Notice given shall be to reduce the number of shares by the number of Terminated Shares (as defined in the Forward Purchase Agreement) specified in such OET Notice with effect as of the related OET Date. As of each OET Date, the Company shall be entitled to an amount from Meteora, and Meteora shall pay to the Company an amount equal to the product of (a) the number of Terminated Shares multiplied by (b) the Initial Price in respect of such OET Date.

The Reset Price is initially \$11.50 and subject to a \$11.50 floor (the "Reset Price Floor"). The Reset Price will be adjusted on the first scheduled trading day of every week commencing with the first week following the seventh day after the closing of the Business Combination to be the lowest of (a) the then-current Reset Price, and (b) the prior week VWAP Price of the shares of Common Stock; provided that the Reset Price shall be no lower than the Reset Price Floor. On July 9, 2023, in connection with the Forward Purchase Agreement, the Sellers entered into a Non-Redemption Agreement with the Company, pursuant to which the Sellers agreed not to exercise redemption rights under the Second Amended Charter with respect to an aggregate of 100,000 shares of Common Stock.

#### Axolotl Biologix Acquisition

On August 9, 2023 (the "Merger Closing Date") August 6, 2024, the Company completed the acquisition of Axolotl Biologix, Inc. ("AxoBio") pursuant to and Meteora entered into an Agreement and Plan of Merger, dated July 26, 2023 (as amended, the "Merger Agreement"), by and among the Company, AxoBio, Aztec Merger Sub, Inc., a wholly owned subsidiary of the Company ("Merger Sub I"), and Axolotl Biologix LLC, a wholly owned subsidiary of the Company ("Merger Sub II"). Upon the closing of the transactions contemplated by the Merger Agreement (the "Merger Closing"), (a) Merger Sub I merged with and into AxoBio, after which the separate corporate existence of Merger Sub I ceased, and AxoBio continued as the surviving corporation, and (b) AxoBio merged with and into Merger Sub II, after which AxoBio ceased to exist, and Merger Sub II survived as a wholly owned subsidiary of the Company (collectively, the "AxoBio Acquisition"). At the effective time of the AxoBio Acquisition (the "Merger Effective Time"), each share of AxoBio's common stock, par value \$0.001 per share ("AxoBio Common Stock"), (other than Dissenting Shares (as defined in the Merger Agreement) and shares held as treasury stock) issued and outstanding as of immediately prior amendment to the Merger Effective Time was canceled and converted into Forward Purchase Agreement to change the right settlement method from physical settlement to receive a pro rata share of:

- \$8,000,000 in cash (the "Closing Cash Consideration"), payable upon delivery of AxoBio's audited financial statements;
- 3,845,337 shares of Common Stock and 4,243 shares of a newly designated series of Series A Convertible Voting Preferred Stock (the "Series A Preferred Stock") issued upon the Merger Closing Date (the "Closing Share Consideration"); and
- up to \$9,000,000 in cash and up to \$66,000,000 in shares of Common Stock that, in each case, were subject to the achievement of certain revenue targets and research and development milestones (the "Earnout").

Settlement. See Note 16 for further information.

## Axolotl Biologix Disposition

On March 20, 2024, the Company entered into a Membership Interest Purchase Agreement (the "Purchase Agreement") with the former stockholders of AxoBio, including Burns Ventures, LLC, a Texas limited liability company ("BVLLC"), H. Rodney Burns, an individual resident of Texas ("Burns"), AXO XP, LLC, an Arizona limited liability company ("AXPLLC"), and Protein Genomics, LLC, a Delaware corporation ("PGEN" and together with BVLLC, Burns, and AXPLLC, collectively, the "Buyers" and each, a "Buyer"), providing for, upon the terms and subject to the conditions set forth therein, the sale by the Company of all outstanding limited liability company interests of AxoBio (the "AxoBio Disposition") to the Buyers for aggregate consideration as described below. The AxoBio Disposition closed on March 26, 2024.

The consideration for the AxoBio Disposition consisted of (i) the Closing Share Consideration, initially issued as consideration to the Buyers under the Merger Agreement, (ii) cancellation of the notes payable to the Buyers in an aggregate principal amount of \$8,000,000 issued as the Closing Cash Consideration in the AxoBio Acquisition and (iii) termination of the Company's obligations with respect to the Earnout.

## Risks and Uncertainties

Disruption of global financial markets and a recession or market correction, including the ongoing military conflicts between Russia and Ukraine and the related sanctions imposed against Russia, as well as the conflict between Israel and Hamas, the ongoing effects of the COVID-19 pandemic, and other global macroeconomic factors such as inflation and rising interest rates, could reduce the Company's ability to access capital, which could in the future negatively affect the Company's liquidity and could materially affect the Company's business and the value of its common stock.

## NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

### Basis of Presentation

The unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The accompanying unaudited condensed consolidated financial statements include all adjustments that are of a normal recurring nature and necessary for the fair presentation of the results for the interim periods presented. Results for interim periods are not necessarily indicative of results to be expected for the full year.

### Emerging Growth Company Status

The Company is an "emerging growth company," as defined in Section 2(a) of the Securities Act of 1933, as amended (the "Securities Act"), as modified by the Jumpstart our Business Startups Act of 2012 (the "JOBS Act"), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the "Exchange Act")), are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company's financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

### Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these financial statements include

those related to the forward purchase asset, earnout liabilities, derivative liabilities, long-term assets and goodwill impairment, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets, and contingent liabilities. If the underlying estimates and assumptions upon which the financial statements are based change in the future, actual amounts may differ from those included in the accompanying financial statements.

#### *Business Combinations*

The Company allocates the fair value of the purchase consideration of its acquisitions to the tangible assets, liabilities, and intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Acquisition-related expenses are expensed as incurred and included in general and administrative expenses.

The allocation of the purchase price requires management to make significant estimates in determining the fair values of assets acquired and liabilities assumed, especially with respect to intangible assets. These estimates are based on information obtained from management of the acquired companies and historical experience. These estimates can include, but are not limited to, the cash flows that an asset is expected to generate in the future and the cost savings expected to be derived from acquiring an asset. These estimates are inherently uncertain and unpredictable, and if different estimates were used, the purchase price for the acquisition could be allocated to the acquired assets and liabilities differently from the allocation that the Company has made.

#### *Discontinued Operations*

On March 26, 2024, the Company completed the AxoBio Disposition as described in Note 1 above. In accordance with Financial Accounting Standards Board Accounting Standards Codification ("ASC") 205, *Presentation of Financial Statements, Discontinued Operations, Other Presentation Matters* ("ASC 205"), the assets and liabilities of AxoBio are classified as available for sale on the accompanying unaudited condensed consolidated balance sheets, and the results of its operations are reported as discontinued operations in the accompanying unaudited condensed consolidated statements of operations.

#### *Segment Reporting*

ASC Topic No. 280, *Segment Reporting* ("ASC 280"), establishes standards for the way that public business enterprises report information about operating segments in their annual consolidated financial statements and requires that those enterprises report selected information about operating segments in interim financial reports. ASC 280 also establishes standards for related disclosures about products and services, geographic areas and major customers. The Company's business segments are based on the organizational structure used by the chief operating decision maker to make operating and investment decisions and assess performance. Our chief executive officer, who is our chief operating decision maker, views the Company's operations and manages its business in one operating segment, which is the business of developing and commercializing aesthetic and regenerative care products.

#### *Cash and Cash Equivalents*

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company's cash and cash equivalents balance exceeds the federally insured limits, which potentially subject the Company to concentrations of credit risk. For the three months ended March 31, 2024 and 2023, the Company has experienced no losses related to its cash and cash equivalents that exceed federally insured deposit limits. As of March 31, 2024, the Company had cash in excess of federally insured limits of \$392,161. As of March 31, 2024 and December 31, 2023, the Company had cash equivalents of \$15,107 and \$30,000, respectively. Cash equivalents as of December 31, 2023 are classified as a component of assets available for sale in the accompanying unaudited condensed consolidated balance sheets.

#### *Accounts Receivables, Net*

Accounts receivable are recorded at the original invoice amount. Receivables are considered past due based on the contractual payment terms. The Company reserves a percentage of its trade receivable balance based on collection history and current economic trends that it expects will impact the level of credit losses over the life of the Company's receivables. These reserves are re-evaluated on a regular basis and adjusted as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve. The Company had no reserve related to the potential likelihood of not collecting its receivables as of March 31, 2024, June 30, 2024 and December 31, 2023. All of the Company's trade receivables were related to AxoBio at December 31, 2023 and are classified as a component of assets available for sale in the accompanying unaudited condensed consolidated balance sheets.

## Inventories

The Company's inventory consists of finished goods and Inventory is stated at the lower of cost or net realizable value. Cost is calculated by applying the first-in-first-out method. The Company regularly reviews inventory quantities on hand and writes down to its net realizable

8

value any inventory that it believes to be impaired. impaired to its net realizable value. Management considers forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining excess and obsolescence and net realizable value adjustments. All At December 31, 2023, all of the Company's inventory was related to AxoBio at December 31, 2023 and is classified as a component of assets available for sale in the accompanying unaudited condensed consolidated balance sheets. The Company had no reserve for obsolescence as of June 30, 2024 and December 31, 2023.

Inventory as of June 30, 2024 was comprised of the following:

	June 30, 2024
Raw materials	\$90,410
Work-in-process	22,607
Finished goods	855
Total	<u>\$113,872</u>

## Property and Equipment

Property and equipment are stated at cost less accumulated depreciation. Maintenance and repair charges are expensed as incurred. Fixed assets are depreciated using the straight-line method using the following estimated useful lives:

- Equipment – 5-7 years
- Leasehold improvements – The lesser of 10 years or the remaining life of the lease
- Furniture and fixtures – 7 years

## Goodwill and Intangible Assets

Goodwill is not amortized but tested for impairment on an annual basis in the fourth quarter and more frequently if events or changes in circumstances indicate that the asset may be impaired. The Company's impairment tests are based on a single reporting unit structure. The carrying value and ultimate realization of these assets is are dependent upon estimates of future earnings and benefits that the Company expects to generate from their use. If the expectations of future results and cash flows are significantly diminished, intangible assets and goodwill may be impaired, and the resulting charge to operations may be material. First, the Company assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. If, after assessing qualitative factors, the Company determines it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is unnecessary. If deemed necessary, a two-step test is used to identify the potential impairment and to measure the amount of goodwill impairment, if any. The first step is to compare the fair value of the reporting unit with its carrying amount, including goodwill. An impairment charge is recognized for the amount by which the carrying amount exceeds the reporting unit's fair value. However, the impairment loss recognized should not exceed the total amount of goodwill allocated to that single reporting unit. All of the Company's goodwill was related to the AxoBio Acquisition and totaled \$19,188,278 as of December 31, 2023, which is classified as a component of assets available for sale in the accompanying unaudited condensed consolidated balance sheets.

Finite-lived intangible assets are carried at cost and amortized based on an economic benefit period, which is seven to twenty years. The Company evaluates finite-lived intangible assets for impairment by assessing the recoverability of these assets whenever adverse events or changes in circumstances or business climate indicate that expected undiscounted future cash flows related to such intangible assets may not be sufficient to support the net book value of such assets. An impairment charge is recognized in the period of identification to the extent the carrying amount of an asset exceeds the fair value of such asset. Costs billed to the Company as reimbursement for third parties' patent submissions are considered to be license fees and are expensed as incurred. Intangible assets related to AxoBio are classified as a component of assets available for sale in the accompanying unaudited condensed consolidated balance sheets.

Finite-lived intangible assets are amortized using the straight-line method using the following useful lives:

- Customer contracts – 20 years
- Trade name – 7 years
- Intellectual property – 7 years
- Patents – 16 years

Significant judgments required in assessing the impairment of goodwill and intangible assets include the assumption the Company only

10

---

has a single reporting unit, identifying whether events or changes in circumstances require an impairment assessment, estimating future cash flows, determining appropriate discount and growth rates and other assumptions. Changes in these estimates and assumptions could materially affect the determination of fair value as to and whether an impairment exists and, if so, the amount of that impairment. The Company has not recognized any goodwill or intangible asset impairment charges in the three six months ended March 31, 2024, June 30, 2024 and 2023.

#### *Series A Voting Convertible Preferred Stock*

In connection with the AxoBio Acquisition, the Company issued 4,243 shares of Series A Preferred Stock to former AxoBio stockholders. Based on the limited exception under ASC 480-10-S99-3A(3)(f) for equity instruments that are subject to a deemed liquidation provision if all of the holders of equally and more subordinated equity instruments of the entity would always be entitled to also receive the same form of consideration (for example, cash or shares) upon the occurrence of the event that gives rise to the redemption (that is, all subordinate classes would also be entitled to redeem), the Company determined that the Series A Preferred Stock should be classified as permanent equity.

9

---

#### *Earnout Liability*

In connection with the AxoBio Acquisition, the former stockholders of AxoBio were entitled to receive the Earnout, consisting of up to \$9,000,000 in cash and up to \$66,000,000 in shares of Common Stock, subject to the achievement of certain revenue targets and research and development milestones. In accordance with ASC 805, Business Combinations ("ASC 805"), the Earnout was included in the purchase price for AxoBio at the Merger Closing Date and subsequently remeasured at each reporting date with changes in fair value recorded as a component of other (expense) income in the accompanying unaudited condensed consolidated statements of operations. As of December 31, 2023, the Company determined that the performance-based targets would not be met and that the Earnout would not be payable.

#### *Revenue Recognition*

The Company accounts for revenue in accordance with ASC 606, Revenue from Contracts with Customers ("ASC 606"). Under ASC 606, revenues are revenue is recognized when control of the promised goods or services is transferred to the a customer in an amount that reflects the consideration that the Company expects to be entitled to receive in exchange for transferring those goods or services. Revenue is recognized based on the following five-step model:

- Identification of the contract with a customer;
- Identification of the performance obligations in the contract;
- Determination of the transaction price;
- Allocation of the transaction price to the performance obligations in the contract; and
- Recognition of revenue when, or as, the Company satisfies a performance obligation.

All of the Company's revenue for the three and six months ended June 30, 2024 was derived from direct-to-consumer sales for which the price is fixed. Such revenue is recognized upon the shipment of the related goods.

#### *Selling and Marketing Expenses*

Selling and marketing expenses relate included in continuing operations principally consist of marketing and advertising expenses. Such costs are expensed as incurred. The Company had no advertising expenses during the three and six months ended June 30, 2024. Selling and marketing expenses related to AxoBio, which are reported as a component of discontinued operations in the accompanying unaudited condensed consolidated statements of operations, totaled \$0 and \$100,000 for the three and six months ended June 30, 2024, respectively. Such expenses consist primarily of advertising expenses, commissions and freight expenses, and the distribution and marketing expenses described previously above in the revenue recognition policies. Sales and marketing expenses were \$100,000 for the three months ended March 31, 2024. These expenses are reported as a component of discontinued operations in the accompanying unaudited condensed consolidated statements of operations.

#### *Research and Development Expenses*

Research and development expenses are expensed as incurred and consist principally of internal and external costs, which include the cost of patent licenses, contract research services, laboratory supplies and development and manufacture of preclinical compounds and consumables for clinical trials and preclinical testing.

#### *Income Taxes*

Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

11

---

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of March 31, 2024, June 30, 2024 and December 31, 2023. The Company is currently not aware of any issues under review that could result in significant payments, accruals, or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities for all tax years subsequent to 2018.

#### *Net Loss Per Share*

Under ASC 260, *Earnings per Share*, the Company is required to apply the two-class method to compute earnings per share ("EPS"). Under the two-class method, both basic and diluted EPS are calculated for each class of common stock and participating security, considering both dividends declared (or accumulated) and participation rights in undistributed earnings. The two-class method results in an allocation of all undistributed earnings as if all those earnings were distributed. Considering that As the Company has generated losses in each reporting period since its inception, the Company also considered the guidance related to the allocation of the undistributed losses under the two-class method. The contractual rights and obligations of the shares of Legacy Preferred Stock (as defined in Note 12.11 below) and the Company's warrants were evaluated to determine if they have an obligation to share in the losses of the Company.

10

As there is no obligation for the holders of Legacy Preferred Stock or the holders of the Company's warrants to fund the losses of the Company, nor is the contractual principal or redemption amount of the shares of Legacy Preferred Stock or the warrants reduced as a result of losses incurred by the Company, under the two-class method, the undistributed losses are allocated entirely to the Common Stock. Earnings per share information has been retrospectively adjusted to reflect the Business Combination ratio applied to Legacy Carmell's historical number of shares outstanding. Shares of Alpha are considered issued for EPS purposes as of the date of the Business Combination.

The Company computes basic loss per share by dividing the loss attributable to holders of Common Stock for the period by the weighted average number of shares of Common Stock outstanding during the period. The Company's warrants, options, Legacy Preferred Stock, and convertible notes could, potentially, be exercised or converted into Common Stock and then share in the earnings of the Company. However, these convertible instruments, warrants, and options were excluded when calculating diluted loss per share because such inclusion would be anti-dilutive for the periods presented. As a result, diluted loss per share is the same as basic loss per share for the periods presented.

Potentially dilutive securities as of June 30, 2024, which are not included in diluted weighted average shares outstanding for the three and six months ended March 31, 2024, June 30, 2024 and 2023, consist of the following (in common stock equivalents):

	For the Three Months Ended March 31,		June 30,	
	2024	2023	2024	2023
Stock Options	1,373,511	2,299,933	1,243,241	2,285,455
Common Stock Warrants	4,617,741	94,554	4,648,222	103,213
Promissory Notes (if settled in shares)	184,961	—	—	—
Legacy Series A Preferred Stock (if converted)	—	1,228,900	—	1,228,900
Legacy Series B Preferred Stock (if converted)	—	2,080,239	—	2,080,239
Legacy Series C-1 Preferred Stock (if converted)	—	313,298	—	313,298
Legacy Series C-2 Preferred Stock (if converted)	—	4,527,149	—	4,527,149
Legacy Preferred Stock Warrants	—	231,291	—	231,291
Convertible Notes (if converted)	—	1,968,320	—	2,118,506
Total	6,176,213	12,743,684	5,891,463	12,888,051

#### Stock-Based Compensation

The Company applies the provisions of ASC 718, *Compensation-Stock Compensation* ("ASC 718"), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees, including employee stock options, in the unaudited condensed consolidated statements of operations.

For stock options issued to employees and members of the Company's Board of Directors (the "Board") for their services, the Company estimates each option's grant-date fair value using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected life of the option, risk-free interest rates, and expected dividend yields of the Common Stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, generally the vesting term. Forfeitures are recorded as incurred instead of estimated at the time of grant and revised.

Under Accounting Standards Update ("ASU") 2018-07, *Compensation - Stock Compensation (Topic 718): Improvements to*

*Non-Employee Share-Based Payment Accounting*, the Company accounts for stock options issued to non-employees for their services in accordance with ASC 718. The Company uses valuation methods and assumptions to value the stock options that are in line with the process for valuing employee stock options noted above.

## Leases

The Company accounts for its leases pursuant to ASC 842, *Leases*, as amended. The Company's leases consist of leaseholds on office space. The Company determines if an arrangement contains a lease at inception as defined by ASC 842. To meet the definition of a lease under ASC 842, the contractual arrangement must convey to the Company the right to control the use of an identifiable asset for a period of time in exchange for consideration. Right of Use ("ROU") assets represent the right to use an underlying asset for the lease

11

term, and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term.

## Concentrations

One customer accounted for 100% of AxoBio's revenues in 2023 and 100% of its accounts receivable at December 31, 2023. AxoBio's human amnion allograft product made up 100% of revenue for the year ended December 31, 2023, which was all purchased from a single vendor, Pinnacle Transplant Technologies, LLC.

## Fair Value Measurements and Fair Value of Financial Instruments

The Company categorizes its assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy below gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The carrying value of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses, deferred consideration payable and related party loans payable approximate fair value because of the short-term maturity of such instruments.

- Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.
- Level 2 - Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liability markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.
- Level 3 - Inputs are unobservable inputs that reflect the reporting entity's assumptions on the assumptions the market participants would use to price an asset or liability based on the best available information.

Other financial assets and liabilities as of March 31, 2024 and December 31, 2023 are categorized based on a hierarchy of inputs as follows:

	March 31, 2024		December 31, 2023		Fair Value Input Hierarchy	June 30, 2024		December 31, 2023		Fair Value Input Hierarchy
	Carrying Value	Estimated Fair Value	Carrying Value	Estimated Fair Value		Carrying Value	Estimated Fair Value	Carrying Value	Estimated Fair Value	
	Forward purchase agreement	\$ 3,543,614	\$ 3,543,614	\$ 5,700,451		\$ 5,700,451	Level 3	\$ 1,420,137	\$ 1,420,137	
SBA Loan	—	—	1,505,070	1,498,000	Level 2	—	—	1,505,070	1,498,000	Level 2

Changes in the fair value of Level 3 financial assets and liabilities for the three six months ended March 31, 2024 June 30, 2024 are as follows:

### Forward Purchase Agreement:

Balance, beginning of year	\$	5,700,451	\$	5,700,451
Change in fair value		(2,156,837)		(4,280,314)
Balance, end of period	\$	3,543,614	\$	1,420,137

The Forward Purchase Agreement was accounted for at fair value as a financial instrument in the scope of ASC 480, *Distinguishing Liabilities from Equity*, and resulted in an asset at the Closing Date. The fair value of the Company's position under the Forward Purchase Agreement was calculated using the Call/Put Option Pricing Model. The assumptions incorporated into the valuation model as of December 31, 2023 included the share price of \$3.81, the termination fee of \$0.50 per share, the debt rate of 12.95% and the term of 0.54 years. As of March 31, 2024 June 30, 2024, the assumptions incorporated into the valuation model included the share price of \$2.56 1.33, the termination fee of \$0.50 per share, a debt rate of 13.07 14.83% and a term of 0.29 0.04 years.

13

### NOTE 3 — BUSINESS COMBINATION

#### *AxoBio Acquisition*

The AxoBio Acquisition is reflected in the unaudited condensed consolidated financial statements under the acquisition method of accounting in accordance with ASC 805, with the Company treated as the accounting and legal acquirer in the AxoBio Acquisition. It was determined that AxoBio is a variable interest entity, as AxoBio's total equity at risk is not sufficient to permit AxoBio to finance its activities without additional subordinated financial support, with the Company being the primary beneficiary. In accordance with ASC 805, the Company recorded AxoBio's assets and liabilities at fair value. For purposes of estimating the fair value, where applicable,

12

of the assets acquired and liabilities assumed as reflected in the unaudited condensed consolidated financial information, the Company has applied the guidance in ASC 820, *Fair Value Measurements and Disclosures* ("ASC 820"), which establishes a framework for measuring fair value in acquisitions. In accordance with ASC 820, fair value is an exit price and is defined as "the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date." Under ASC 805, acquisition-related transaction costs are not included as components of consideration transferred but are accounted for as expenses in the period in which the costs are incurred. The fair value of the purchase consideration transferred in the AxoBio Acquisition was as follows:

Common Stock - 3,845,337 shares	\$	11,270,683
Series A Convertible Voting Preferred Stock - 4,243 shares		10,382,107
Earnout		13,482,292
Deferred Consideration		8,000,000
<b>Total estimated value of consideration transferred</b>	<b>\$</b>	<b>43,135,082</b>

The fair value of the Series A Preferred Stock was estimated at \$2,447 per share, using the put option model, based on the market value of the Common Stock at the Merger Closing Date, conversion rate, projected conversion term, and estimated discount for lack of marketability. Deferred consideration is related to the Closing Cash Consideration of \$8,000,000, that was payable upon delivery of the AxoBio 2022 audited financial statements. The 2022 audited financial statements were delivered in October 2023, and as such, the cash consideration was payable at December 31, 2023.

In connection with the AxoBio Acquisition, the former stockholders of AxoBio were entitled to receive payment of the Earnout consisting of up to \$9,000,000 in cash and up to \$66,000,000 in shares of Common Stock, subject to the achievement of certain revenue targets and research and development milestones. In accordance with ASC 815-40, as the Earnout was not indexed to the Common Stock, it was accounted for as a liability at the Merger Closing Date and is subsequently remeasured at each reporting date with changes in fair value recorded as a component of discontinued operations in the accompanying unaudited condensed consolidated statements of operations.

The fair value of the Earnout was estimated as of the Merger Closing Date using (1) the probabilities of success and estimated dates of milestone achievements in relation to the research and development milestones, and (2) probability-adjusted revenue scenarios in relation to the revenue targets.

The total purchase consideration transferred in the AxoBio Acquisition has been allocated to the net assets acquired and liabilities assumed based on their fair values at the acquisition date. The transaction costs related to this acquisition of approximately \$1,300,000 were expensed and included in the transaction-related expenses on the accompanying unaudited condensed consolidated statements of operations.

14

The allocation of the purchase price was as follows:

Total estimated value of consideration transferred	\$	43,135,082
Cash and cash equivalents		662,997
Accounts receivable		18,296,000
Prepaid expenses		170,604
Inventories		10,600,000
Property and equipment		81,846
Intangible assets		23,260,000
Total assets		53,071,447
Accounts payable		12,767,909
Accrued interest		146,829
Other accrued expenses		1,390,278
Loan payable		1,498,000
Related party loans		5,610,000
Deferred tax liabilities		7,711,627
Net assets to be acquired		23,946,804
Goodwill	\$	19,188,278

The Company estimated the fair value of the acquired inventories based on the selling price less costs to sell and recorded the fair value step-up of approximately \$8,200,000 at the Merger Closing Date. The fair value step-up is amortized over the expected realization term of one year from the Merger Closing Date.

13

The acquired loan payable of AxoBio was adjusted down to its fair value by \$502,000 due to the more favorable than the market interest rate. This fair value step down is amortized over the term of loan payable as a credit to the interest expense.

The intangible assets include trade names, customer contracts and intellectual property. The intangible assets were valued using a discounted cash flow model. The estimated fair value of the customer contracts as of the acquisition date was determined based on the projected future profits from the contracts, discounted to present value, and the likelihood of contract renewals at the end of each contract term. The estimated fair value of the intellectual property as of the acquisition date was determined based on the estimated license royalty rates, the present value of future cash flows from the intellectual property, and the expected useful life of 7

years. The estimated fair value of the trade name was determined based on the estimated royalty rates for the use of the trade name, the projected revenues attributable to the trade name discounted to present value and the expected useful life of 7 years. The goodwill and other intangible assets associated with the AxoBio Acquisition are not deductible for U.S. tax purposes.

The Company determined that the AxoBio Acquisition was deemed significant to the Company in accordance with Rule 3-05 of Regulation S-X. As required by ASC 805, *Business Combinations*, the following unaudited pro forma statements of operations for the three and six months ended March 31, 2023 and June 30, 2023 give effect to the AxoBio Acquisition as if it had been completed on January 1, 2022 and January 1, 2023. The unaudited pro forma financial information below is presented for illustrative purposes only and is not necessarily indicative of what the operating results actually would have been during the periods presented had the AxoBio Acquisition been completed during the periods presented. In addition, the unaudited pro forma financial information does not purport to project future operating results. The pro forma statements of operations do not fully reflect: (i) any anticipated synergies (or costs to achieve synergies) or (ii) the impact of non-recurring items directly related to the AxoBio Acquisition.

	<b>For the three months ended March 31, 2023</b>
Revenue included in discontinued operations in the consolidated statements of operations	\$ —
Add: AxoBio revenue not reflected in the consolidated statements of operations	9,398,658
Unaudited pro forma revenue	<u>\$ 9,398,658</u>
	<u>\$ —</u>
Net loss from consolidated statements of operations	\$ (1,828,715)
Add: AxoBio net income not reflected in the consolidated statements of operations, less pro forma adjustments described below <sup>(1)</sup>	(2,636,041)
Unaudited pro forma net loss	<u>\$ (4,464,756)</u>

15

	<b>For the three months ended June 30, 2023</b>	<b>For the six months ended June 30, 2023</b>
Revenue included in discontinued operations in the consolidated statements of operations	\$ —	\$ —
Add: AxoBio revenue not reflected in the consolidated statements of operations	12,521,575	21,920,233
Unaudited pro forma revenue	<u>\$ 12,521,575</u>	<u>\$ 21,920,233</u>
	<u>\$ (5,308,952)</u>	<u>\$ (7,137,667)</u>
Net loss from consolidated statements of operations	\$ (5,308,952)	\$ (7,137,667)
Add: AxoBio net income not reflected in the consolidated statements of operations, less pro forma adjustments described below <sup>(1)</sup>	(953,566)	(3,457,472)
Unaudited pro forma net loss	<u>\$ (6,262,518)</u>	<u>\$ (10,595,139)</u>

(1) An adjustment to reflect amortization of \$598,459 and \$1,196,916 for three and the three six months ended March 31, 2023 and June 30, 2023, respectively, that would have been charged assuming the fair value adjustments to intangible assets had been applied on January 1, 2023. The adjustment also reflects additional costs of goods sold of \$2,037,582 and \$4,075,164 for the three and six months ended March 31, 2023 and June 30, 2023, respectively, that would have been charged assuming the fair value step up to inventories had been applied on January 1, 2023.

#### NOTE 4 — GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS

The Historically, the Company's liquidity needs historically have been satisfied through debt and equity financing. As of March 31, 2024 June 30, 2024, the Company had cash of \$892,161 2,198,275 and an accumulated deficit of \$61,774,360 65,078,898. In addition, the Company had a net loss from continuing operations of \$3,553,162 6,857,700 and negative cash flows from operations of \$1,075,778 2,214,254 for the three six months ended March 31, 2024 June 30, 2024.

Due to its current liabilities and other potential liabilities, the cash available to the Company may not be sufficient to allow the Company to operate for at least 12 months from the date these unaudited condensed consolidated financial statements are available for issuance. The Company may need to raise additional capital through equity or debt issuances. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations and reducing payroll expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all.

These conditions raise substantial doubt about the Company's ability to continue as a going concern. These unaudited condensed consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

14

In April 2024, the Company sold 1,331,452 shares of its Common Stock for gross proceeds of \$3,001,235 (see Note 15 - Subsequent Events). In addition, the The Company has refocused its efforts on aesthetic cosmetic skincare products that have with near-term commercial potential, reprioritized its research and development, and ceased clinical studies of product candidates that will take more than a year to commercialize. The Company is also exploring the development and commercialization of haircare products based on the Carmell Secretome™ and out-licensing of certain research and development programs to generate non-dilutive liquidity.

16

#### NOTE 5 — PROPERTY AND EQUIPMENT

Property and equipment consist of the following:

	March 31,	December 31, 2023		June 30, 2024	December 31, 2023	
	2024	2023			Continuing Operations	Continuing Operations
	Continuing Operations	Continuing Operations	Discontinued Operations	Continuing Operations	Continuing Operations	Discontinued Operations
Lab equipment	\$ 696,648	\$ 696,648	\$ 216,210	\$ 696,648	\$ 696,648	\$ 216,210
Leasehold improvements	115,333	115,333	—	115,333	115,333	—
Furniture and fixtures	3,580	3,580	30,057	3,580	3,580	30,057
	815,561	815,561	246,267	815,561	815,561	246,267
Less: accumulated depreciation	(645,114)	(622,715)	(182,883)	(667,512)	(622,715)	(182,883)
Property and equipment, net	\$ 170,447	\$ 192,846	\$ 63,384	\$ 148,049	\$ 192,846	\$ 63,384

Depreciation expense included in loss from continuing operations in the accompanying unaudited condensed consolidated statements of operations was \$22,399, \$22,398 and \$22,971, \$25,147 for the three months ended March 31, 2024, June 30, 2024 and 2023, respectively, and \$44,797 and \$48,118 for the six months ended June 30, 2024 and 2023, respectively. Depreciation expense included in discontinued operations in the accompanying unaudited condensed consolidated statements of operations was \$10,828 for the three six months ended March 31, 2024, June 30, 2024.

#### NOTE 6 —GOODWILL AND INTANGIBLE ASSETS

The Company's goodwill relates to the AxoBio Acquisition. Goodwill represents the excess of the purchase price of the acquired business over the fair value of the underlying net tangible and intangible assets. The Company may record goodwill adjustments pursuant to changes in the preliminary valuations acquired during the measurement period, which is up to one year from the date of acquisition. For the year ended December 31, 2023, the Company recognized \$19,188,278 in goodwill from the AxoBio Acquisition, which is classified as a component of assets available for sale in the accompanying unaudited condensed consolidated balance sheets.

The Company capitalizes legal costs directly associated with the submission of Company patent applications. Gross patent costs of \$70,746 as of March 31, 2024, June 30, 2024 are amortized on a straight-line basis over the patent term.

Intangible assets acquired in connection with the AxoBio Acquisition were initially recorded at their estimated fair value as of the acquisition date (see Note 3 - Business Combination). Intangible assets that have finite lives are amortized over their economic useful life. Amortization of intangibles related to AxoBio are included as a component of discontinued operations in the accompanying unaudited condensed consolidated statements of operations.

Intangible assets and the related accumulated amortization consist of the following at March 31, 2024, June 30, 2024:

	Amortization Period	Gross Carrying Value	Accumulated Amortization	Net Book Value	Amortization Period	Gross Carrying Value	Accumulated Amortization	Net Book Value
Continuing operations:								
Patents	16 years	\$ 70,746	\$ 47,691	\$ 23,055	16 years	\$ 70,746	\$ 48,823	\$ 21,923

15

Intangible assets and the related accumulated amortization consist of the following at December 31, 2023:

	Amortization Period	Gross Carrying Value	Accumulated Amortization	Net Book Value
Continuing operations:				
Patents	16 years	\$ 70,746	\$ 46,559	\$ 24,187
Discontinued operations:				
Customer contracts	20 years	\$ 12,170,000	\$ 337,313	\$ 11,832,687
Trade name	7 years	2,220,000	132,143	2,087,857
Intellectual property	7 years	8,870,000	527,976	8,342,024
		\$ 23,260,000	\$ 997,432	\$ 22,262,568

17

Amortization expense included in loss from continuing operation in the accompanying unaudited condensed consolidated statements of operations was \$1,132 and \$1,128 for the three months ended **March 31, 2024** **June 30, 2024** and 2023, respectively, and \$2,264 and \$2,256 for the six months ended **June 30, 2024** and 2023, respectively. Amortization expense included in income from discontinued operation in the accompanying unaudited condensed consolidated statements of operations was \$625,621 for the **three** six months ended **March 31, 2024** **June 30, 2024**.

Amortization expense related to the Company's intangible assets for the remainder of 2024 and future years is as follows:

2024 (remainder)	\$	3,396
2025		4,516
2026		4,516
2027		4,090
2028		2,451
Thereafter		4,086
	<b>\$</b>	<b>23,055</b>

#### NOTE 7— ACCRUED EXPENSES AND OTHER LIABILITIES

Accrued expenses and other liabilities consist of the following amounts:

	March 31, 2024		December 31, 2023		June 30, 2024		December 31, 2023	
	Continuing Operations	Continuing Operations	Discontinued Operations	Continuing Operations	Continuing Operations	Discontinued Operations	Continuing Operations	Discontinued Operations
Accrued severance	\$ 220,683	\$ 452,579	\$ —	\$ 104,140	\$ 452,579	\$ —	\$ —	\$ —
Accrued compensation	56,832	790,332	—	19,332	790,332	—	—	—
Accrued stock-based compensation	48,698	48,698	—	—	48,698	—	—	—
Other accrued expenses	242,132	303,825	468,652	212,154	303,825	468,652	—	—
Accrued expenses and other liabilities	<b>\$ 568,345</b>	<b>\$ 1,595,434</b>	<b>\$ 468,652</b>	<b>\$ 335,626</b>	<b>\$ 1,595,434</b>	<b>\$ 468,652</b>	<b>\$ —</b>	<b>\$ —</b>

Accrued compensation is a non-interest bearing liability for employee payroll outstanding as of **March 31, 2024** **June 30, 2024** and December 31, 2023. This includes compensation earned during the years 2019 to 2023.

#### NOTE 8 —DEBT

##### U.S. Small Business Administration (SBA) Loan

As of the Merger Closing Date, AxoBio had an outstanding loan with the SBA with total principal and accrued interest outstanding of \$2,000,000 and \$113,476, respectively (the "SBA Loan"). Interest under the SBA Loan accrues at a simple interest rate of 3.75% annually on funds outstanding as of the anniversary date of the initial borrowing. A monthly payment in the amount of \$9,953 began in December 2023 and continues for a total of 30 years. As of December 31, 2023, there was outstanding principal and accrued interest of \$2,000,000 and \$134,961, respectively. As of December 31, 2023, there was unamortized debt discount of \$494,930. In connection with the AxoBio Acquisition, the SBA Loan was adjusted to fair value, which, excluding accrued interest, was determined to be \$1,498,000. The difference in the outstanding principal and fair value of \$502,000 was recorded as debt discount and is **accrued** **amortized** over the remaining

term of the loan using the effective interest method. For the three and six months ended March 31, 2024 June 30, 2024, the Company incurred interest expense of \$0 and \$17,571, respectively, and amortization of debt discount of \$17,571 and \$4,242, respectively. The SBA Loan and related accrued interest are classified as a component of assets available for sale in the accompanying unaudited condensed consolidated balance sheets, and the related interest expense and amortization of debt discount are classified as a component of discontinued operations in the accompanying unaudited condensed consolidated statements of operations.

#### Related Party Loans

As of the Merger Closing Date, AxoBio had several promissory notes outstanding to Burns Ventures, LLC (the "Burns Notes") with total principal outstanding of \$5,610,000. The owner of Burns Ventures LLC was a former stockholder of AxoBio. Interest on the Burns Notes is payable quarterly at a fixed interest rate of 7.00%. The Burns Notes require no monthly payments and are due in full at maturity date on December 31, 2024. As of December 31, 2023, the Burns Notes had outstanding principal and accrued interest of \$5,610,000 and \$98,982, respectively, and interest expense totaled \$0 and \$89,448 for the three and six months ended March 31, 2024 June 30, 2024. The Burns Notes and related accrued interest are classified as a component of assets available for sale in the accompanying unaudited condensed consolidated balance sheet, and the related interest expense is classified as a component of discontinued operations in the accompanying unaudited condensed consolidated statements of operations.

#### 2023 Promissory Notes

During the year ended December 31, 2023, the Company received proceeds of \$848,500 from 26 zero coupon Promissory Notes (the "Promissory Notes"). Four of the Promissory Notes were from related parties and represented \$100,000 of the borrowings. The Promissory Notes have had a maturity date of one year from the date of issuance. The principal of the Promissory Notes is was due in full at maturity. All Promissory Notes had a proportionate number of Common Stock warrants for 16,489 shares of Common Stock issued in connection with the issuance of the Promissory Notes. There were 16,489 Common Stock warrants issued in connection with the Promissory Notes with a fair value of \$55,062. The These warrants vested immediately, and have a term of 5 years, and exercise prices ranging from \$11.50 to \$14.30. The fair value of the these warrants was recorded as debt discount and is amortized over the term of the loans using the effective interest method. As of March 31, 2024, there Debt discount amortization was outstanding principal and unamortized debt discount of \$473,500 6,081 and \$6,081 7,597, respectively. Debt discount amortization during respectively, for the three months ended March 31, 2024 June 30, 2024 and 2023 was and \$13,468 19,549 and \$703 8,300, for the six months ended June 30, 2024 and 2023, respectively. Pursuant to the terms of the Promissory Notes, the Board elected to repay all maturities of the Promissory

18

Notes in shares of Common Stock. During the three six months ended March 31, 2024 June 30, 2024, the Company issued 115,820 328,707 shares of Common Stock related to repay the maturity of Promissory Notes with an aggregate principal value amount of \$375,000 848,500.

#### Insurance Premium Financing

The In August 2024, the Company has entered into agreements an agreement with a third parties, whereby it financed party to finance a total \$1,011,480 premium on an insurance policy. This financing agreement had a monthly payment amount of \$1,043,018 117,072, accrued interest at a rate of premiums on certain of its insurance policies (the "Premium Financing Programs"). The Premium Financing Programs accrue interest between 8.99%, and matured in April 2024. As of June 30, 2024 and December 31, 2023, there was \$0 and \$459,647, respectively, of principal outstanding under this financing agreement.

In April 2024, the Company entered into another agreement with a third party to finance a \$31,538 premium on a new insurance policy. This financing agreement has a monthly payment amount of \$2,761, accrues interest in the amount of 9.99% and have a total monthly payments matures in February 2025. As of \$119,833 June 30, 2024 and December 31, 2023, with the last payment due in March 2025. The remaining principal outstanding on these loans there was \$263,921 21,286 as and \$0, respectively, of March 31, 2024 principal outstanding under this financing agreement.

During the three and six months ended June 30, 2024, interest expense totaled \$11,566 3,264 for the three months ended March 31, 2024, and \$14,830, respectively, on these financing agreements.

#### January 2022 Convertible Notes

On January 19, 2022, the Company issued two senior secured convertible notes (the “Convertible Notes”) of \$1,111,111 each to two investors (the “Holders”), due on January 19, 2023. The Convertible Notes bore interest at 10% (18% upon default). The Company was required to make monthly interest payments for the interest incurred and required monthly principal payments of \$158,730 beginning on July 19, 2022. The Convertible Notes were collateralized by all assets (including current and future intellectual property) of Legacy Carmell. The Convertible Notes were issued with a 10% discount and were subject to an 8% commission due to the underwriter. These fees were recorded as debt discount. In addition, each of the Holders received warrants to subscribe for and purchase up to 155,412 shares of Common Stock (the “Convertible Note Warrants”). Each Convertible Note Warrant is exercisable at a price of \$0.16 per warrant share, vested immediately, and has a term of five years. The fair value of the Convertible Note Warrants at the time of issuance was \$409,483, which was recorded as debt discount. The Convertible Notes are convertible at the option of the Holders into shares of Common Stock at a fixed conversion price equal to the lesser of \$3.57 per share and a 25% discount to the price of the Common Stock in a Qualified Offering (as defined in the Convertible Notes) (as adjusted, the “Conversion Price”). In the event units consisting of Common Stock and warrants are issued in a Qualified Offering, the Convertible Notes are convertible into Common Stock and warrants. If, at any time while the Convertible Notes are outstanding, the Company sells or grants any option to purchase or sells or grants any right to repurchase, or otherwise disposes of or issues (or announces any sale, grant or any option to purchase or other disposition), any Common Stock or Common Stock equivalents entitling any person to acquire shares of Common Stock at an effective price per share that is lower than the then Conversion Price (such lower price, the “Base Conversion Price”), then the Conversion Price shall be reduced to equal the Base Conversion Price. Such adjustments are to be made whenever such Common Stock or Common Stock equivalents are issued. Multiple events have triggered the down-round feature of the base conversion price. As of December 31, 2022, the Base Conversion Price was \$1.79.

17

---

The conversion feature within the Convertible Notes met the requirements to be treated as a derivative. Accordingly, the Company estimated the fair value of the Convertible Notes derivative using the Monte Carlo Method as of the date of issuance. The fair value of the derivative was determined to be \$1,110,459 at the time of issuance and was recorded as a liability with an offsetting amount recorded as a debt discount. The derivative is revalued at the end of each reporting period, and any change in fair value is recorded as a gain or loss in the unaudited condensed consolidated statements of operations.

Proceeds from the sales of the Convertible Notes with Convertible Note Warrants were allocated to the two elements based on the relative fair value of the Convertible Notes without the warrants and the warrants themselves at the time of issuance. The total amount allocated to the Convertible Note Warrants was \$409,483 and accounted for as paid-in capital. The discount amount was calculated by determining the aggregate fair value of the warrants using the Black-Scholes option pricing model.

On July 19, 2022, Carmell defaulted on the Convertible Notes. Under the terms of the Convertible Notes, upon an event of default, there would be a 25% increase to the outstanding principal, in addition to the interest rate increasing from 10% to 18%. Upon the event of default, the unamortized debt discount of \$958,899 was accelerated and expensed, and the 25% increase in outstanding principal of \$555,556 was recorded as interest expense.

#### *An Agreement Subsequent to the Notice of Acceleration*

On November 2, 2022, Carmell received a letter (“Notice of Acceleration”) from one of the Holders, notifying it of an Event of Default under the Convertible Notes. Carmell and Alpha entered into an agreement with such Holder, Puritan Partners LLC (“Puritan”), in connection with the Notice of Acceleration on December 19, 2022. Pursuant to this agreement, Alpha and Carmell each represented and

19

---

warranted to Puritan that (i) it intended to enter into the Business Combination, (ii) there would be no conditions to closing relating to Alpha or its affiliates delivering a certain amount of cash to the Company at closing of the Business Combination, (the “Closing”), (iii) the only conditions to the closing of the Business Combination were as set forth in Sections 6.1 through Section 6.3 of the Business Combination Agreement, (iv) upon entering into such Business Combination Agreement, such parties would have a commitment letter from a third party to provide capital in an amount sufficient to the surviving company of the Business Combination to,

among other things, repay all amounts due and owing at such time to Puritan at the closing, (v) the equity valuation ascribed to Carmell in the Business Combination Agreement was \$150,000,000, and (vi) such Business Combination Agreement shall not place any restrictions on Puritan's ability to transfer any of its securities, including, without limitation, the shares underlying its Convertible Note Warrants. Carmell agreed it would not pay any other debtholder on account of interest or principal during the forbearance period.

Based on the representations, and warranties and agreements above and in consideration of Carmell's agreement to pay Puritan at the closing of the Business Combination (i) the outstanding principal amount, plus accrued interest, late fees and all other amounts then owed as specified in the Convertible Notes and (ii) 25,000 freely tradeable shares of Common Stock (not subject to lock-up or any other restrictions on transfer) at a price of \$10.00 per share (i.e., the price per share of Common Stock to the equity holders of Carmell in the Business Combination), Puritan withdrew and rescinded the Notice of Acceleration, and such Notice of Acceleration was deemed null and void and had no further force or effect. Puritan further agreed that, based on the representations and warranties, and agreements contained in such agreement, it shall not issue any further notices of acceleration or default notices under the Convertible Notes, seek repayment of any amounts due under the Convertible Notes, or seek to exercise any other remedies contained in the Convertible Notes and other related agreements in regard to non-payment of the Convertible Notes from the date of the Notice of Acceleration until June 30, 2023.

On the closing of the Business Combination, the Company repaid \$2,649,874 to the Holders, which represented the original principal amount of the Convertible Notes plus accrued interest at a rate of 25%, which the Company believes is the maximum rate permissible under New York State usury laws. In addition, the Company issued Puritan 25,000 freely tradeable shares of Common Stock. Following the closing of the Business Combination, both Holders have provided notice to the Company demanding additional payment of principal and interest on the Convertible Notes in an approximate amount of \$600,000 per each Holder at the closing of the Business Combination with additional interest thereon. In the case of Puritan, following the Business Combination, Puritan alleged that the Business Combination constituted a "Fundamental Transaction" under the terms of the Convertible Note Warrants, resulting in a purported right for Puritan to require the Company to repurchase such Convertible Note Warrants at a purchase price equal to the Black-Scholes Value of the unexercised portion of such Convertible Note Warrants as of the closing of the Business Combination. Puritan calculated the cash amount of such repurchase to be \$1,914,123. The Company believes that this calculation is inaccurate. The other Holder demanded to be provided its share of the Convertible Note Warrants. Puritan has also asserted damages in connection with the timing of the issuance to it of 25,000 freely tradeable shares of Common Stock. The Company believes that it provided freely tradeable shares to Puritan at the same time as other Legacy Carmell stockholders. Puritan's total claims, inclusive of the amounts paid at the Closing Date, exceed \$4,050,000 in connection with a loan for which the Company received \$1,000,000. Management of the Company believes that its obligations under the Convertible Notes and Convertible Note Warrants have been satisfied and that no additional payments are due to the Holders, and the Company has conveyed its position to the Holders. There can be no assurance that these or similar matters will not result in expensive arbitration, litigation or other dispute resolution, which may not be resolved in our favor and may adversely impact our financial condition (see Note 109 - Commitments and Contingencies).

18

## NOTE 9 — LEASES

The Company is a party to two office leases, each of which expire on December 31, 2028. The Company elected to not recognize ROU assets and lease liabilities arising from short-term leases (leases with initial terms of twelve months or less, which are deemed immaterial) on its consolidated balance sheets.

When measuring lease liabilities for leases that were classified as operating leases, the Company discounted lease payments using its estimated incremental borrowing rate at the later of lease inception or January 1, 2020 (the date of adoption). The weighted average incremental borrowing rate applied was 8%.

The following table presents net lease cost and other supplemental lease information:

	For the three months ended March 31,	
	2024	2023
Lease cost:		
Operating lease cost	\$50,423	\$50,423
Short-term lease cost	—	—
Net lease cost	\$50,423	\$52,446
Cash paid for operating lease liabilities	\$34,839	\$31,413

The estimated future minimum lease payments, excluding non-lease components, for the remainder of 2024 and future years are as follows:

Operating

Fiscal Year	Leases
2024 (remainder)	\$ 153,698
2025	204,930
2026	204,930
2027	204,930
2028	204,930
Total future minimum annual lease payments	973,418
Less: Imputed interest	(160,416)
Present value of lease liabilities	\$ 813,002

## NOTE 10 — COMMITMENTS AND CONTINGENCIES

### Exclusive License Agreement

On January 30, 2008, the Company and Carnegie Mellon University (“CMU”) entered into a License Agreement, as amended by that certain Amendment No. 1 to License Agreement, dated as of July 19, 2011, as further amended by that certain Amendment No. 2 to License Agreement, dated as of February 8, 2016, as further amended by that certain Amendment No. 3 to License Agreement, dated as of February 27, 2020 and as further amended by that certain Amendment No. 4 to License Agreement, dated November 23, 2021 (collectively, the “Amended License Agreement”). The Amended License Agreement provides the Company an exclusive, worldwide right to use certain technology of CMU relating to biocompatible plasma-based plastics to make, have made, use, and otherwise dispose of licensed products and to create derivatives for the field of use. The Company is required to use its best efforts to effect the introduction of the licensed technology into the commercial market as soon as possible and meet certain milestones as stipulated within the Amended License Agreement. CMU retains the right to use any derivative technology developed by the Company due to its use of this technology and retains the intellectual property rights to the licensed technology, including patents, copyrights, and trademarks.

The Amended License Agreement is effective until January 30, 2028, or until the expiration of the last-to-expire patent relating to this technology, whichever comes later, unless otherwise terminated under another provision within the Amended License Agreement. Failure to perform in accordance with the agreed-upon milestones is grounds for CMU to terminate the Amended License Agreement prior to the expiration date. As a partial royalty for the license rights, the Company issued 66,913 shares of Common Stock to CMU. In

20

addition, in 2008, the Company issued a warrant which was exercised in full in 2011 for 98,938 shares of Common Stock. Prior to a qualified initial public offering or a qualified sale, CMU has the right to subscribe for additional equity securities to maintain its then percentage of ownership in the Company. The Business Combination did not qualify as a qualified initial public offering or qualified sale under the Amended License Agreement.

19

Royalties payable by the Company to CMU are 2.07% of net sales, as defined in the Amended License Agreement. The Company is also required to pay CMU 25% of any sublicense fees received, due, and payable upon receipt of the sublicense fees by the Company. All payments due to CMU are due within sixty (60) days after the end of each fiscal quarter. All overdue payments bear interest at a rate equal to the Prime Rate (as defined in the Amended License Agreement) in effect at the date such amounts are due plus 4%. No royalties were accrued or paid during the three and six months ended March 31, 2024, June 30, 2024 and 2023.

The Company is obligated to reimburse CMU for all patent expenses and fees incurred to date by CMU for the licensed technology at the earlier of (1) three years from the effective date of the Amended License Agreement; (2) the closing date of a change in control event; and (3) for international patents, from the start of expenses for patenting outside of the United States of America. There were no reimbursed expenses and no owed related to reimbursable expenses for the three and six months ended March 31, 2024, June 30, 2024 and 2023.

#### *Convertible Notes*

As detailed in Note 8 - Debt, both Holders have provided notice to the Company demanding additional payment of principal and interest on the Convertible Notes in an approximate amount of \$600,000 per each Holder at the closing of the Business Combination with additional interest thereon. In the case of Puritan, following the Business Combination, Puritan alleged that the Business Combination constituted a "Fundamental Transaction" under the terms of the Convertible Note Warrants, resulting in a purported right for Puritan to require the Company to repurchase such Convertible Note Warrants at a purchase price equal to the Black-Scholes Value of the unexercised portion of such Convertible Note Warrants as of the closing of the Business Combination. Puritan calculated the cash amount of such repurchase to be \$1,914,123. The Company believes that this calculation is inaccurate. The other Holder demanded to be provided its share of the Convertible Note Warrants. Puritan has also asserted damages in connection with the timing of the issuance to it of 25,000 freely tradeable shares of Common Stock. The Company believes that it provided freely tradeable shares to Puritan at the same time as other Legacy Carmell stockholders. Puritan's total claims, inclusive of the amounts paid at Closing Date, exceed \$4,050,000 in connection with a loan for which the Company received \$1,000,000. Management of the Company believes that its obligations under the Convertible Notes and Convertible Note Warrants have been satisfied and that no additional payments are due to the Holders, and the Company has conveyed its position to the Holders. As described in further detail below, Puritan has filed a complaint against the Company related to these allegations. There can be no assurance that these or similar matters will not result in further arbitration, litigation or other dispute resolution, which may not be resolved in our favor and may adversely impact our financial condition.

#### *Puritan Litigation*

On November 8, 2023, Puritan filed a complaint captioned Puritan Partners LLC v. Carmell Regen Med Corporation et al., No. 655566/2023 (New York Supreme Court, New York County) naming the Company as a defendant. In the complaint, Puritan asserts that the Company breached its obligations under the Convertible Notes and the Convertible Note Warrants. Puritan also asserts the Company did not timely comply with its obligations to provide Puritan with 25,000 freely tradeable shares of Common Stock. Puritan asserts claims for declaratory judgment, breach of contract, conversion, foreclosure of its security interest, replevin, unjust enrichment, and indemnification, and seeks remedies, including damages totaling \$2,725,000 through November 1, 2023, additional fees and interest thereafter, costs and attorney's fees, an order of foreclosure on its security interest, and other declaratory relief. The Company has moved to dismiss the complaint and intends to defend itself vigorously against this litigation. There can be no assurance that this matter will be resolved in the Company's favor, and an adverse outcome could have a material adverse effect on the Company's financial condition.

#### **NOTE 11.10 — PROFIT-SHARING PLAN**

The Company has 401(k) profit-sharing plans covering substantially all employees. The Company's discretionary profit-sharing contributions are determined annually by the Board. No discretionary profit-sharing contributions were made to the plans during the three and six months ended March 31, 2024, June 30, 2024 and 2023.

#### **NOTE 12.11 — STOCKHOLDERS' EQUITY (DEFICIT)**

##### *Common Stock*

As of March 31, 2024, June 30, 2024 and December 31, 2023, the Company's Third Amended and Restated Certificate of Incorporation, as amended at the Closing Date, Company was authorized the Company to issue 250,000,000 shares of Common Stock. Stock and had 20,905,407 and 23,090,585, respectively, shares issued and outstanding. In conjunction with the AxoBio Disposition on March 26, 2024, 3,845,337 shares of Common Stock were returned to the Company and retired. As

On April 4, 2024, the Company entered into a securities purchase agreement with certain investors for the sale of March 31, 2024, there were an aggregate of 19,361,068 1,331,452 shares of Common Stock outstanding for gross proceeds of \$3,001,235 (the "Private Placement"). In conjunction with the Private Placement, the Company issued a warrant for 89,787 shares of Common Stock to the placement agent on April 11, 2024. This warrant has an exercise price of \$2.81, a term of 5 years, a fair value of \$129,495, and becomes exercisable six months after issuance. In conjunction with the Private Placement, the Company owed \$212,212 in fees and \$25,000 in legal costs to the placement agent, which were recorded as a reduction of the gross proceeds received. There were no payables to the placement agent as of June 30, 2024. The placement agent is a related party, as a member of the Board is a managing partner of the placement agent.

20

#### *Series A Voting Convertible Preferred Stock*

In connection with the AxoBio Acquisition, the Company issued 4,243 shares of Series A Preferred Stock to former stockholders of AxoBio. In conjunction with the AxoBio Disposition on March 26, 2024, such shares were returned to the Company and were retired.

#### *Convertible Preferred Stock*

Immediately prior to the Business Combination, Legacy Carmell had outstanding Series A convertible preferred stock ("Legacy Series A Preferred Stock"), Series B convertible preferred stock ("Legacy Series B Preferred Stock"), Series C-1 convertible preferred stock ("Legacy Series C-1 Preferred Stock") and Series C-2 convertible preferred stock ("Legacy Series C-2 Preferred Stock"), which are collectively referred to herein as "Legacy Preferred Stock."

Legacy Series A Preferred Stock, Legacy Series C-1 Preferred Stock, and Legacy Series C-2 Preferred Stock accrued cumulative dividends at a per annum rate of 7% calculated on the original issue price (the "Original Issue Price"), respectively. Such dividends accrued on each share of Legacy Preferred Stock commencing on the date of issuance. The Company accrued dividends of \$75,084, \$18,716, and \$217,368 for Legacy Series A Preferred Stock, Legacy Series C-1 Preferred Stock, and Legacy Series C-2 Preferred Stock, respectively, for the three months ended March 31, 2023.

In connection with the Business Combination, all previously issued and outstanding shares of Legacy Preferred Stock were converted into an equivalent number of shares of Common Stock on a one-for-one basis, then multiplied by the Exchange Ratio pursuant to the Business Combination Agreement.

#### *2023 Long-Term Incentive Plan*

In July 2023, the stockholders of the Company approved the 2023 Long-Term Incentive Plan (the "2023 Plan"), which replaced the Amended and Restated 2009 Stock Incentive Plan of Legacy Carmell (the "2009 Plan"). No new awards are being made under the 2009 Plan. Under the 2023 Plan, the Board may grant awards of stock options, stock appreciation rights, restricted stock, restricted stock units or other stock-based awards to employees and other recipients as determined by the Board. The exercise price per share for an option granted to employees owning stock representing more than 10% of the Company at the time of the grant cannot be less than 110% of the fair market value. Incentive and non-qualified stock options granted to all persons shall be granted at a price no less than 100% of the fair market value and any price determined by the Board. Options expire no more than ten years after the date of the grant. Incentive stock options to employees owning more than 10% of the Company expire no more than five years after the date of grant. The vesting of stock options is determined by the Board. Generally, the options vest over a four-year period at a rate of 25% one year following the date of grant, with the remaining shares vesting equally on a monthly basis over the subsequent thirty-six months.

The maximum number of shares that may be issued under the 2023 Plan is the sum of: (i) 1,046,408, (ii) an annual increase on January 1, 2024 and each anniversary of such date prior to the termination of the 2023 Plan, equal to the lesser of (a) 4% of the outstanding shares of our Common Stock determined on a fully diluted basis as of the immediately preceding year-end and (b) such smaller number of shares as determined by the Board or the compensation committee of the Board, and (iii) the shares of Common Stock subject to 2009 Plan awards, to the extent those shares are added into the 2023 Plan by operation of the recycling provisions described below.

The initial maximum number of shares of Common Stock that may be issued under the 2023 Plan through incentive stock options is was 1,046,408 1,046,385, provided that this limit will automatically increase increases on January 1 of each year, for a period of not more than ten years, commencing on January 1, 2024 and ending on (and including) January 1, 2032, by an amount equal to the lesser of 1,500,000 shares or the number of shares added to the share pool as of such

January 1, as described in clause (ii) of the preceding sentence. The following shares will be added (or added back) to the shares available for issuance under the 2023 Plan:

- Shares subject to 2009 Plan or 2023 Plan awards that expire, terminate or are canceled or forfeited for any reason after the effectiveness of the 2023 Plan;
- Shares that after the effectiveness of the 2023 Plan are withheld to satisfy the exercise price of an option issued under the 2009 Plan or 2023 Plan;
- Shares that after the effectiveness of the 2023 Plan are withheld to satisfy tax withholding obligations related to any award under the 2009 Plan or 2023 Plan; and

22

- Shares that after the effectiveness of the 2023 Plan are subject to a stock appreciation right that are not delivered on exercise or settlement.

However, the total number of shares underlying 2009 Plan awards that may be recycled into the 2023 Plan pursuant to the above-described rules will not exceed the number of shares underlying 2009 Plan awards as of the effective date of the 2023 Plan (as adjusted to reflect the Business Combination). Shares of Common Stock issued through the assumption or substitution of awards in connection with a future acquisition of another entity will not reduce the shares available for issuance under the 2023 Plan.

21

#### Warrant and Option Valuation

The Company computes the fair value of warrants and options granted using the Black-Scholes option pricing model. The expected term used for warrants and options issued to non-employees is the contractual life, and the expected term used for options issued to employees and directors is the estimated period that options granted are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” grants for stock options. The Company utilizes an expected volatility figure based on a review of the historical volatilities over a period equivalent to the expected life of the instrument valued by similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued. The Company’s stock price was derived from a 409A valuation prior to the Business Combination and market price for all options and warrants granted thereafter.

#### Warrants Outstanding

A summary of the Common Stock warrant activity during the three six months ended March 31, 2024 June 30, 2024 is as follows:

	Number of Warrants	Weighted Average Exercise Price	Weighted Average Remaining Contractual Life in Years	Aggregate Intrinsic Value
Outstanding and exercisable, December 31, 2023	4,638,454	\$ 10.20	4.62	\$ 1,382,919
Issued	—	—		
Exercised	—	—		
Expired	(20,713)	6.87		
Outstanding and exercisable, March 31, 2024	4,617,741	\$ 10.16	4.27	\$ 777,855

Weighted

	Number of Warrants	Weighted Average Exercise Price	Weighted Average Remaining Contractual Life in Years	Aggregate Intrinsic Value
Outstanding, December 31, 2023	4,638,454	\$ 10.20	4.62	\$ 1,382,919
Issued	89,787	2.81		
Expired	(80,019)	6.75		
Outstanding, June 30, 2024	4,648,222	\$ 10.11	4.11	\$ 362,887
Exercisable, June 30, 2024	4,558,435	\$ 10.25	4.10	\$ 362,887

#### Option Activity and Summary

A summary of the option activity during the three six months ended March 31, 2024 June 30, 2024 is as follows:

	Number of Options	Weighted Average Exercise Price	Weighted Average Remaining Life in Years	Aggregate Intrinsic Value	Number of Options	Weighted Average Exercise Price	Weighted Average Remaining Life in Years	Aggregate Intrinsic Value
Outstanding, December 31, 2023	1,689,765	\$ 2.72	9.00	\$ 1,850,397	1,689,765	\$ 2.72	9.00	\$ 1,850,397
Granted	70,000	3.57			112,981	3.05		
Expired/Cancelled	(386,254)	2.90			(559,505)	2.75		
Outstanding, March 31, 2024	1,373,511	\$ 2.71	8.44	\$ 193,527				
Vested/Exercisable, March 31, 2024	332,737	\$ 2.16	5.75	\$ 149,501				
Outstanding, June 30, 2024	1,243,241	\$ 2.74	8.35	\$ —				
Vested/Exercisable, June 30, 2024	278,182	\$ 2.21	5.53	\$ —				

The weighted average fair value of the options granted during the three six months ended March 31, 2024 June 30, 2024 was based on a Black Scholes option pricing model using the following assumptions:

Expected volatility	70.0%
Expected term of option	6.0 - 7.0
Range of risk-free interest rate	3.8% -4.3% -4.6%
Dividend yield	0%

The Company recorded stock-based compensation expense for related to its options of \$211,469 163,700 and \$180,509 187,030 for the three months ended March 31, 2024 June 30, 2024 and 2023, respectively, and \$375,169 and \$367,539 for the six months ended June 30, 2024 and 2023, respectively. As

of March 31, 2024 June 30, 2024, 2023, there was \$1,765,553 1,662,811 of unrecognized compensation expense related to unvested stock options, which will be recognized over the weighted average remaining vesting period of 2.58 2.46 years.

#### NOTE 13.12 – INCOME TAXES

The Company did not record any income tax provision or benefit for the three and six months ended March 31, 2024 June 30, 2024 and 2023. The Company provides for a valuation allowance when it is more likely than not that it will not realize a portion of its deferred tax assets. The Company has established a valuation

allowance against the net deferred tax asset due to the uncertainty that enough taxable income will be

22

generated in those taxing jurisdictions to utilize the assets. Therefore, we have not reflected any benefit of such deferred tax assets in the accompanying unaudited condensed consolidated financial statements.

**NOTE 14.13 – DISCONTINUED OPERATIONS**

On March 20, 2024, the Company entered into the Purchase Agreement to sell AxoBio and closed the AxoBio Disposition on March 26, 2024 as detailed in Note 1. The assets and liabilities of AxoBio are classified as available for sale in the accompanying unaudited condensed consolidated balance sheets and consist of the following:

	March 31, 2024		December 31, 2023		June 30, 2024		December 31, 2023	
<b>Assets available for sale</b>								
Cash and cash equivalents	\$	—	\$	804,277	\$	—	\$	804,277
Accounts receivable, net		—		7,713,600		—		7,713,600
Prepaid expenses		—		251,086		—		251,086
Inventories		—		3,038,179		—		3,038,179
Property and equipment, net		—		63,384		—		63,384
Intangible assets, net		—		22,262,568		—		22,262,568
Goodwill		—		19,188,278		—		19,188,278
<b>Total assets available for sale</b>	<b>\$</b>	<b>—</b>	<b>\$</b>	<b>53,321,372</b>	<b>\$</b>	<b>—</b>	<b>\$</b>	<b>53,321,372</b>
<b>Liabilities available for sale</b>								
Accounts payable	\$	—	\$	8,520,243	\$	—	\$	8,520,243
Accrued interest		—		134,961		—		134,961
Accrued interest, related party		—		98,982		—		98,982
Other accrued expenses		—		468,652		—		468,652
Loans payable, current		—		1,505,070		—		1,505,070
Related party loans, current		—		5,610,000		—		5,610,000
Earnout liability		—		8,000,000		—		8,000,000
Deferred income taxes		—		5,536,923		—		5,536,923
<b>Total liabilities available for sale</b>	<b>\$</b>	<b>—</b>	<b>\$</b>	<b>29,874,831</b>	<b>\$</b>	<b>—</b>	<b>\$</b>	<b>29,874,831</b>

24

The significant components of discontinued operations in the accompanying unaudited condensed consolidated statements of income are as follows:

	For the Three Months Ended March 31,	For the Six Months Ended June 30,
--	---	--------------------------------------

	2024	2023	2024	2023
Revenue	\$ —	\$ —		
Cost of sales	—	—		
Gross profit	—	—		
Operating expenses:				
Selling and marketing	\$ 100,000	\$ —	\$ 100,000	\$ —
Research and development	89,972	—	89,972	—
General and administrative	470,686	—	470,686	—
Depreciation and amortization	636,449	—	636,449	—
Total operating expenses	1,297,107	—	1,297,107	—
Loss from operations	(1,297,107)	—	(1,297,107)	—
Other income (expense):				
Amortization of debt discount	(4,242)	—	(4,242)	—
Interest expense, related party	(89,448)	—	(89,448)	—
Interest expense	(17,571)	—	(17,571)	—
Total other (expense) income	(111,261)	—	(111,261)	—
Loss before income taxes	(1,408,368)	—	(1,408,368)	—
Income tax benefit, deferred	156,092	—	156,092	—
Discontinued operations, net	\$ (1,252,276)	\$ —	\$ (1,252,276)	\$ —

23

#### NOTE 15.14 – SUBSEQUENT EVENTS

On April 4, 2024,

In July 2024, the Company entered into a securities purchase agreement with certain investors named therein issued options for the sale of an aggregate of 1,331,452 1,358,893 shares of Common Stock at pursuant to the 2023 Plan with a weighted average exercise price of \$2.25 1.07 per share for unaffiliated investors share. These options vest over four years (with 25% vesting after one year and at the remainder vesting 1/36th per month over the balance of the vesting period) and expire after ten years from the date of grant.

On July 16, 2024, the Company was notified by Meteora of a potential Event of Default under the Forward Purchase Agreement (the "Default Notice"). On August 6, 2024, the Company and Meteora amended the Forward Purchase Agreement (the "FPA Amendment") to change the settlement method from physical settlement to cash settlement. Pursuant to the FPA Amendment, Meteora waived any potential Event of Default referred to in the Default Notice and agreed to make a cash payment to the Company on the tenth business day immediately following the last day of the Valuation Period (as defined below) in an amount equal to (i) 1,705,959 shares of Common Stock subject to the Forward Purchase Agreement multiplied by the daily volume-weighted average price over the Valuation Period, less (ii) 1,705,959 shares of Common Stock multiplied by \$2.88 0.75 per share for the Company's Chief Executive Officer (the "Private Placement"). The purchase price per share to be paid by the Company's Chief Executive Officer "Valuation Period" is defined in the Private Placement reflects FPA Amendment as the closing sale price period commencing on July 14, 2024 (the "Valuation Date") and ending at 4:00 p.m. on the trading day on which 10% of the total volume traded in shares of Common Stock on The Nasdaq Capital Market on April 3, 2024. has reached an amount equal to the number of shares of Common Stock outstanding as of the Valuation Date.

The Private Placement closed on April 11, 2024, and Board appointed Kendra Bracken-Ferguson as Chief Executive Officer of the Company received gross proceeds effective as of \$3,001,235 July 30, 2024. In conjunction with Ms. Bracken-Ferguson's appointment as Chief Executive Officer, Rajiv Shukla resigned from his position as Chief Executive Officer of the Private Placement. Also in connection with Private Placement, Company. Following his resignation, Mr. Shukla continues to serve as Executive Chairman of the Company issued 89,787 Common Stock warrants with an exercise price of \$2.81 and a term of 5 years. Board.

24 25

## Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the accompanying unaudited condensed consolidated financial statements and the related notes contained in Part I, Item 1 of this Quarterly Report on Form 10-Q (this "Quarterly Report") and our audited consolidated financial statements and the notes thereto, Part I – Item 1A, "Risk Factors" and Part II – Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the "2023 Annual Report"). Unless the context requires otherwise, references in this Quarterly Report to "Carmell," the "Company," "we," "us," or "our," prior to the closing of the Business Combination (as defined in Note 1 to the accompanying unaudited condensed consolidated financial statements), are intended to refer to Carmell Therapeutics Corporation, a Delaware corporation, ("Legacy Carmell") and, after the closing of the Business Combination, are intended to refer to Carmell Corporation, a Delaware corporation, and its consolidated subsidiaries.

### Cautionary Statement Regarding Forward-Looking Statements

This Quarterly Report includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Exchange Act. We have based these forward-looking statements on our current expectations, assumptions and projections about future events. These forward-looking statements are subject to involve known and unknown risks and uncertainties that are difficult to predict and assumptions about us that may could cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "could," "would," "expect," "plan," "future," "intend," "anticipate," "likely," "believe," "estimate," "continue," or the negative of such terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements include, but are not limited to, statements and expectations regarding the launch and commercialization of our products, our ability to raise financing in the future, our success in retaining or recruiting key members of our management, the benefits of and our expectations related to the AxoBio Disposition and the Private Placement, market acceptance of our products, regulatory developments related to the cosmetics industry, our ability to compete in our industry, our need to grow the size of our organization in the future and the management of such growth, outcomes related to legal proceedings, as well as all other statements other than statements of historical fact included in this Quarterly Report. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other SEC filings we make with the U.S. Securities and Exchange Commission (the "SEC"), including those described under the section entitled Part II, Item 1A, "Risk Factors" in this Quarterly Report and under Part I, Item 1A, "Risk Factors" in the 2023 Annual Report. These forward-looking statements represent our Annual Report on Form 10-K for estimates and assumptions as of the fiscal year ended December 31, 2023 (the "2023 Annual Report"), filing date of this Quarterly Report. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

### Overview

Carmell is a bio-aesthetics company that utilizes the Carmell Secretome™ to support skin and hair health. The Carmell Secretome™ consists of a potent cocktail of growth factors and proteins extracted from allogeneic human platelets sourced from U.S. Food and Drug Administration-approved tissue banks. Over the past seven years, Carmell has extensively tested the technology underpinning the Carmell Secretome™. In addition, we have developed a novel microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen™, which are 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. Additionally, Carmell's microemulsion formulations do not utilize mineral or vegetable oils across its entire product line and are designed to be non-comedogenic. We We are also developing a line of men's products and a line of topical haircare products. All of our cosmetic skincare and haircare products are tailored to meet the demanding technical requirements of professional care providers and discerning retail consumers. Our product pipeline also includes innovative regenerative bone and tissue healing products that are under development.

We are developing and have started to commercially launch our line of cosmetic skincare products in the first half of 2024. We plan to employ an omni-channel distribution strategy and sell our products online through direct e-commerce channels and through retailers and distributors in the United States. In addition, we plan to sell our doctor dispensed products through dermatology and plastic surgery practices and medical aesthetics centers.

### Recent Developments

#### Appointment of Chief Executive Officer

The Board appointed Kendra Bracken-Ferguson as Chief Executive Officer of the Company effective as of July 30, 2024. Ms. Bracken-Ferguson, age 44, is the Founder and Chief Executive Officer of BrainTrust, which encompasses BrainTrust Agency, BrainTrust Founders Studio and BrainTrust Fund 1. She has vast

experience in the digital media space and has excelled at developing revenue-generating partnerships in the beauty and wellness industries. Ms. Bracken-Ferguson has served as Chief Executive Officer of BrainTrust Founders Studio since October 2021 and as the Chief Executive Officer of BrainTrust Fund since 2022. She was previously the interim

26

---

Chief Executive Officer of rē•spin by Halle Berry from April 2020 until October 2021. From May 2019 to April 2020, she was the Chief Business Officer of Beautycon Media. Ms. Bracken-Ferguson has helped develop more than 200 influencer-driven brands that have collectively generated more than \$100 million in revenue. She currently serves on the growth advisory board of Iced Media, and previously served on the board of directors of Cayton Children's Museum, the board of directors of Influencer Marketing Association and the advisory board of BeautyUnited. Ms. Bracken-Ferguson earned her bachelor's degree from Purdue University and an MBA from Keller School of Management, DeVry University.

In conjunction with Ms. Bracken-Ferguson's appointment as Chief Executive Officer, Rajiv Shukla resigned from his position as our Chief Executive Officer. Following his resignation, Mr. Shukla continues to serve as Executive Chairman of the Board.

#### *Sale of Common Stock*

On April 11, 2024, we closed the Private Placement, in which we sold to certain accredited investors an aggregate of 1,331,452 shares of Common Stock, at a price of \$2.25 per share for unaffiliated investors and at a price of \$2.88 per share for our former Chief Executive Officer. The purchase price per share paid by our former Chief Executive Officer in the Private Placement reflected the closing sale price of the Common Stock on The Nasdaq Capital Market on April 3, 2024. We received gross proceeds of \$3,001,235 from the Private Placement. In connection with the Private Placement, we issued to the placement agent a warrant for 89,787 shares of Common Stock with an exercise price of \$2.81 and a term of five years. We also incurred \$314,009 in fees and legal costs related to the Private Placement, which was recorded as a reduction of the gross proceeds received. A member of the Board is a managing partner of the placement agent. See Note 11 to the accompanying unaudited condensed consolidated financial statements for additional information regarding the Private Placement.

#### *Axolotl Biologix Disposition*

On March 20, 2024, we entered into the Purchase Agreement with the Buyers, the former stockholders of AxoBio, for the AxoBio Disposition. The AxoBio Disposition, as contemplated by the Purchase Agreement, closed on March 26, 2024. In connection with the AxoBio Disposition, upon the terms and subject to the conditions set forth in the Purchase Agreement, we sold all of the outstanding limited liability company interests of AxoBio to the Buyers in exchange for the return of the Closing Share Consideration, the cancellation of the notes payable by the Company to the Buyers in an aggregate principal amount of \$8,000,000 issued as the Closing Cash Consideration and termination of the Company's obligations with respect to the Earnout. See Note 1 to the accompanying unaudited condensed consolidated financial statements for additional information regarding the AxoBio Disposition.

25

---

In accordance with ASC 205, the assets and liabilities of AxoBio are classified as available for sale on the accompanying unaudited condensed consolidated balance sheets, and the results of its operations are reported as discontinued operations in the accompanying unaudited condensed consolidated statements of operations.

#### ***Sale of Common Stock***

On April 4, 2024, we entered into a securities purchase agreement with certain investors named therein for the sale of an aggregate of 1,331,452 shares of Common Stock, at a price of \$2.25 per share for unaffiliated investors and at a price of \$2.88 per share for the Company's Chief Executive Officer in the "Private Placement" (as defined in Note 15 to the accompanying unaudited condensed consolidated financial statements). The purchase price per share to be paid by our Chief Executive Officer in the Private Placement reflects the closing sale price of the Common Stock on The Nasdaq Capital Market on April 3, 2024. The Private Placement closed on April 11, 2024, and we received gross proceeds of \$3,001,235 from the Private Placement. In connection with the Private Placement, we issued 89,787 Common Stock warrants with an exercise price of \$2.81 and a term of five years.

### **Impact of Macroeconomic Events**

Economic uncertainty in various global markets caused by political instability and conflicts, such as the ongoing conflicts in Ukraine and Israel, rising tensions in the Middle East, and economic challenges have led to market disruptions, including significant volatility in commodity prices, credit and capital market instability, and supply chain interruptions, which have caused record inflation globally. Our business, financial condition, and results of operations could be materially and adversely affected by further negative impacts on the global economy and capital markets resulting from these global economic conditions, particularly if such conditions are prolonged or worsen. Although, to date, our results of operations have not been materially impacted by these global economic and geopolitical conditions, it is impossible to predict the extent to which our operations may be impacted in the short and long term. The extent and duration of these market disruptions, whether as a result of the military conflict between Russia and Ukraine, the effects of the Russian sanctions, the conflict between Israel and Hamas, geopolitical tensions, inflation, or otherwise, are impossible to predict. Any such disruptions may also magnify the impact of other risks described or incorporated by reference in Part II, Item 1A. "Risk Factors" in this Quarterly Report and Part I, Item 1A, "Risk Factors" in our 2023 Annual Report.

### **Critical Accounting Policies and Estimates**

This discussion and analysis of our financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, as well as the reported revenue expenses and net loss incurred during the reporting periods. Our estimates are based on our historical experience and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

27

### **Going Concern and Management Plan**

The unaudited condensed consolidated financial statements included elsewhere herein for the three months ended March 31, 2024, were prepared under the assumption that we would continue our operations as a going concern, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. However, as of March 31, 2024 June 30, 2024, we had cash of \$892,161, \$2,198,275, an accumulated deficit of \$61,774,360 \$65,078,898 and liabilities of \$7,572,002, \$6,405,627. We have incurred substantial recurring losses from continuing operations, have used, rather than provided, cash from our continuing operations and are dependent on additional financing to fund future operations. These conditions raise substantial doubt about our ability to continue as a going concern within one year after the date the financial statements are issued. The unaudited condensed consolidated financial statements included elsewhere herein do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

The Company We closed on the Private Placement in April 2024 and received gross proceeds of \$3,001,235. In addition, we expect the sale of AxoBio, which closed on March 26, 2024, to further reduce our operating expenses. Furthermore, we have refocused our efforts on aesthetic cosmetic skincare products that have with near-term commercial potential, reprioritized further research and development, and ceased clinical studies of product candidates that will take more than a year to commercialize. We are also exploring the development and commercialization of haircare products based on the Carmell Secretome™ and out-licensing certain research and development programs to generate non-dilutive liquidity. Collectively, these activities are anticipated to assist us in extending our cash runway.

26

**Comparison of Results of Operations for the Three Months Ended March 31, 2024 June 30, 2024 and 2023**

The following table sets forth our results of operations for the three months ended March 31, 2024 June 30, 2024 and 2023:

	For the Three Months Ended				For the three months ended			
	March 31,		Change	%	June 30,		Change	%
	2024	2023			2024	2023		
	(unaudited)							
Revenue	\$ 12,320	\$ —	\$ 12,320	100%				
Cost of goods sold	292	—	292	100%				
Gross profit	12,028	—	12,028	100%				
Operating expenses:								
Selling and marketing	11,045	—						
Research and development	\$ 429,420	\$ 740,325	\$ (310,905)	-42%	104,066	823,657	(719,591)	-87%
General and administrative	927,394	510,445	416,949	82%	1,064,874	637,453	427,421	67%
Depreciation and amortization of intangibles	23,531	24,101	(570)	-2%	23,530	26,274	(2,744)	-10%
Total operating expenses	1,380,345	1,274,871	105,474	8%	1,203,515	1,487,384	(283,869)	-19%
Loss from operations	(1,380,345)	(1,274,871)	(105,474)	8%	(1,191,487)	(1,487,384)	295,897	-20%
Other expenses, net	(2,172,817)	(553,844)	(1,618,973)	292%	(2,113,051)	(3,821,568)	1,708,517	-45%
Net loss income before taxes	\$ (3,553,162)	\$ (1,828,715)	\$ (1,724,447)	94%				
Net loss from continuing operations before taxes	\$ (3,304,538)	\$ (5,308,952)	\$ 2,004,414	-38%				

**Revenue/Gross Profit**

Revenue for the three months ended June 30, 2024 was \$12,320 and reflects the launch of our first three cosmetic skincare products in the later part of the second quarter of 2024. Our cost of goods and gross profit on these sales were \$292 and \$12,028, respectively.

**Operating Expenses**

Total operating Selling and marketing expenses were \$1,380,345 and \$1,274,871 totaled \$11,045 for the three months ended March 31, 2024 June 30, 2024 and 2023, respectively. This increase reflects a higher level of expenses resulting from were driven by the execution costs related to our initial marketing endeavors related to the launch of our strategic plan to commercialize our technologies. first three cosmetic skincare products in the later part of the second quarter of 2024.

Research and development expenses decreased from \$740,325 for by \$719,591 to \$104,066 in the three months ended March 31, 2023 second quarter of 2024 as compared to \$429,420 for the three months ended March 31, 2024 same period of 2023. This decrease was driven by our strategic realignment, which refocused our efforts on aesthetic cosmetic skincare products that have with near-term commercial potential, reprioritized further research and development, and ceased clinical studies of product candidates that will take more than a year to commercialize. Also contributing to the decrease was the termination of employees in non-core or overlapping business areas in the third quarter of 2023, 2023 and the first quarter of 2024.

General and administrative expenses were \$927,394 \$1,064,874 and \$510,445 \$637,453 for the three months ended March 31, 2024 June 30, 2024 and 2023, respectively. This increase was primarily driven by an increase in insurance costs and salaries and benefits for personnel.

Depreciation and amortization expense decreased slightly to \$23,531 for the three months ended March 31, 2024 as compared to \$24,101 for the comparable period of 2023.

**Other Expenses, Net**

Other expenses, net, were \$2,172,817 \$2,113,051 for the three months ended March 31, 2024 June 30, 2024, as compared to \$553,844 \$3,821,568 in the comparable corresponding period of 2023. The increase between periods was primarily due to Other expenses, net, for the second quarter of 2024 were driven by an unfavorable change in the fair value of the Forward

Purchase Agreement of \$2,156,837, \$2,123,477, partially offset by a decrease of \$238,266 \$265,173 in interest expense, and the amortization of debt discount, reflecting a lower level of average debt outstanding. In addition, the The corresponding period of 2023 period includes an unfavorable change in the fair value of derivative liabilities related to the Convertible Notes of \$325,085. \$3,545,073.

#### Comparison of Results of Operations for the Six Months Ended June 30, 2024 and 2023

The following table sets forth our results of operations for the six months ended June 30, 2024 and 2023:

	For the Six Months Ended June 30,		Change	% Change
	2024	2023		
	(unaudited)			
Revenue	\$ 12,320	\$ —	\$ 12,320	100%
Cost of goods sold	292	—	292	
Gross profit	12,028	—	12,028	100%
Operating expenses:				
Selling and marketing	11,045	—	11,045	100%
Research and development	533,486	1,563,982	(1,030,496)	-66%
General and administrative	1,992,268	1,147,898	844,370	74%
Depreciation and amortization of intangibles	47,061	50,375	(3,314)	-7%
Total operating expenses	2,583,860	2,762,255	(178,395)	-6%
Loss from operations	(2,571,832)	(2,762,255)	190,423	-7%
Other expenses, net	(4,285,868)	(4,375,412)	89,544	-2%
Net loss income before taxes	\$ (6,857,700)	\$ (7,137,667)	\$ 279,967	-4%

#### Revenue/Gross Profit

Revenue for the six months ended June 30, 2024 was \$12,320 and reflects the launch of our first three cosmetic skincare products in the later part of the second quarter of 2024. Our cost of goods and gross profit on these sales were \$292 and \$12,028, respectively.

#### Operating Expenses

Selling and marketing expenses totaled \$11,045 for the six months ended June 30, 2024 and were driven by the costs related to our initial marketing endeavors related to the initial launch of our cosmetic skincare products.

Research and development expenses decreased by \$1,030,496 to \$533,486 in the first six months of 2024 as compared to the same period of 2023. This decrease was driven by our strategic realignment, which refocused our efforts on cosmetic skincare products with near-term commercial potential, reprioritized further research and development, and ceased clinical studies of product candidates that will take more than a year to commercialize. Also contributing to the decrease was the termination of employees in non-core or overlapping business areas in the third quarter of 2023 and the first quarter of 2024.

General and administrative expenses were \$1,992,268 and \$1,147,898 for the six months ended June 30, 2024 and 2023, respectively. This increase was primarily driven by an increase in insurance costs and salaries and benefits for personnel.

#### Other Expenses, Net

Other expenses, net, were \$4,285,868 for the six months ended June 30, 2024, as compared to \$4,375,412 in the corresponding period of 2023. For the six months ended June 30, 2024, other expenses, net, was driven by an unfavorable change in the fair value of the Forward Purchase Agreement of \$4,280,314, partially offset by a decrease of \$516,204 in interest expense, reflecting a lower level of average debt outstanding. The same period of 2023 includes an unfavorable change in the fair value of derivative liabilities related to the Convertible Notes of \$3,870,158.

#### Discontinued Operations, Net

The Company We had a loss from discontinued operations of \$1,252,276, net of tax, in 2024, for the six months ended June 30, 2024, which reflects the results of the AxoBio business through the closing of the AxoBio Disposition on March 26, 2024. There have been no sales of AxoBio's products since October 2023. The Company recognized a non-cash gain on the sale of AxoBio of \$1,534,479 during the six months ended June 30, 2024, due principally to the change in the fair value of the stock consideration between the AxoBio Acquisition and the AxoBio Disposition. See Note 1 to the accompanying unaudited condensed consolidated financial statements.

29

---

### Liquidity, Capital Resources, and Going Concern

As of March 31, 2024 June 30, 2024, we had cash of \$892,161 \$2,198,275 and an accumulated deficit of \$61,774,360 \$65,078,898. In addition, we had a net loss from continuing operations of \$6,857,700 and negative cash flows from operations of \$2,214,254 for the six months ended June 30, 2024. Since our inception, we have financed operations principally through public and private issuances of equity securities and debt financing. In addition to the cost savings from the elimination of non-core areas or overlapping business functions in both the third quarter of 2023 and the expected first quarter of 2024 and the reduction of expenses resulting from the AxoBio Disposition, we have refocused our efforts on aesthetic cosmetic skincare products that have with near-term commercial potential, and have reprioritized further research and development, and ceased clinical studies of product candidates that will take more than a year to commercialize.

27

---

During Late in the second quarter of 2024, we intend to launch a line of launched our first three cosmetic skincare products based on the technologies we developed through our research and development activities, Carmell Secretome™. Management anticipates that revenue from the commercialization of its cosmetic skincare products and the anticipated cost savings from the activities detailed above will assist us in extending our cash runway. In addition, we are exploring the development and commercialization of haircare products based on the Carmell Secretome™ and out-licensing of certain research and development programs to generate non-dilutive liquidity.

However, the cash available to us may not be sufficient to allow us to operate for the next 12 months due to our current and potential liabilities. We may need to raise additional capital through equity or debt issuances. If we are unable to raise additional capital, we may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations and reducing overhead expenses. We cannot provide any assurance that new financing will be available on commercially acceptable terms, if at all, or will be completed on a timely basis. These conditions raise substantial doubt about our ability to continue as a going concern.

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with GAAP, which contemplates the continuation of the Company as a going concern, the realization of assets, and the satisfaction of liabilities in the normal course of business. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty or that may be necessary should we be unable to continue as a going concern.

### Debt

As of March 31, 2024 June 30, 2024, we had outstanding indebtedness with principal debt totaling \$736,577 \$21,286 (Note 8 to the accompanying unaudited condensed consolidated financial statements). In the first quarter of 2024, the Board elected to repay all of the maturing Promissory Notes in shares of the Company's Common Stock in accordance with the terms of the Promissory Notes. During the three six months ended March 31, 2024 June 30, 2024, \$375,000 all of the Promissory Notes matured and with an aggregate principal amount of \$848,500 were repaid through the issuance of 115,820 an aggregate of 328,707 shares of Common Stock. The Promissory Notes remaining outstanding, with a total principal amount of \$473,500, will mature during the second quarter of 2024. In

addition, the Holders of the Convertible Notes have demanded additional payment of principal and interest on the Convertible Notes and certain payments with respect to the Convertible Note Warrants, as more fully described in Note 109 to the accompanying unaudited condensed consolidated financial statements.

### Cash Flows

The following table summarizes our cash flows for the three six months ended March 31, 2024 June 30, 2024 and 2023:

	Three Months Ended March 31,			Six Months Ended June 30,		
	2024	2023	Change	2024	2023	Change
Net cash used in operating activities	\$ (1,075,778)	\$ (475,959)	\$ (599,819)	\$ (2,214,254)	\$ (956,137)	\$ (1,258,117)
Net cash used in investing activities	(748,796)	—	(748,796)	(748,796)	(30,470)	(718,326)
Net cash (used in) provided by financing activities	(195,726)	375,000	(570,726)			
Net cash provided by financing activities	2,248,864	874,378	1,374,486			

### Operating Activities

Net cash used in operating activities for the three six months ended March 31, 2024 June 30, 2024 increased by \$599,819 \$1,258,117 as compared to the comparable same period of 2023. This increase was primarily driven by net cash used in AxoBio's operations the payment of \$1,033,586. Also contributing to the increase were decreases in accounts payable and accrued expenses and an increase in prepaid expenses.

### Investing Activities

For the three six months ended March 31, 2024 June 30, 2024, we paid \$748,796 of costs in connection with the AxoBio Disposition.

### Financing Activities

Net cash used in provided by financing activities was \$195,726 \$2,248,864 for the three six months ended March 31, 2024 June 30, 2024, as compared to net cash provided by financing activities of \$375,000 \$874,378 for the three six months ended March 31, 2023 June 30, 2023. In the 2024 period, six months ended June 30, 2024, we closed the Private Placement, which provided net proceeds of \$2,687,225. In addition, we repaid \$227,264 \$469,899 of principal related to our Premium Financing Programs, insurance financing programs described in Note 8 to the

30

accompanying unaudited condensed consolidated financial statements, while we received \$375,000 \$848,500 in proceeds from the issuance of the Promissory Notes in the 2023 period. See Note 8 to our accompanying unaudited condensed consolidated financial statements for details regarding our Premium Financing Programs, six months ended June 30, 2023.

### Contingencies

On November 8, 2023, Puritan filed a complaint captioned Puritan Partners LLC v. Carmell Regen Med Corporation et al., No. 655566/2023 (New York Supreme Court, New York County) naming the Company as defendant. In the complaint, Puritan asserts that the Company breached its obligations under the Convertible Notes and the Convertible Note Warrants. Puritan also asserts the Company

28

did not comply with its obligations to provide Puritan with 25,000 freely tradeable shares of Common Stock on a timely basis. Puritan asserts claims for declaratory judgment, breach of contract, conversion, foreclosure of its security interest, replevin, unjust enrichment, and indemnification, and seeks remedies including damages totaling \$2,725,000 through November 1, 2023, additional fees and interest thereafter, costs and attorney's fees, an order of foreclosure on its security interest, and other declaratory relief. The Company has moved to dismiss the complaint and intends to defend itself vigorously against this litigation.

### **Contractual Obligations and Commitments**

In addition to financing obligations under our debt agreements, our contractual and commercial commitments include expenditures for operating leases and royalty payments. For further information on our Amended License Agreement with CMU see Note 10.9 to the accompanying unaudited condensed consolidated financial statements.

### **Emerging Growth Company and Smaller Reporting Company Status**

The JOBS Act permits an "emerging growth company" to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. Although we qualify as an emerging growth company, we have elected not to "opt-out" of this provision and, as a result, we will adopt new or revised accounting standards at the time private companies adopt the new or revised accounting standard and will do so until such time that we either (i) irrevocably elect to "opt-out" of such extended transition period or (ii) no longer qualify as an emerging growth company.

We are also a "smaller reporting company," meaning that the market value of our stock held by non-affiliates is less than \$700 million, and our annual revenue was less than \$100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than \$250 million or (ii) our annual revenue was less than \$100 million during the most recently completed fiscal year, and the market value of our stock held by non-affiliates is less than \$700 million. If we are a smaller reporting company at the time that we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.

31

---

### **Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

Not required.

### **Item 4. Controls and Procedures.**

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

### **Evaluation of Disclosure Controls and Procedures**

As required by Rules 13a-15 and 15d-15 under the Exchange Act, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, carried out an evaluation of the effectiveness of our disclosure controls and procedures as of **March 31, 2024** **June 30, 2024**. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were **not** effective as of such **date**. **date due to the issue described below.**

### **Changes in Internal Control Over Financial Reporting**

There has been no change Management identified a material weakness in our internal control controls over financial reporting the accounting treatment for a complex transaction during the most recently completed fiscal quarter that has materially affected, or is reasonably likely ended June 30, 2024. They have addressed this weakness by adopting a policy requiring formal documentation to materially affect, our internal control over financial reporting, substantiate the accounting treatment of all material transactions, including references to the relevant authoritative guidance.

29 32

## PART II—OTHER INFORMATION

### Item 1. Legal Proceedings.

For a description of our material pending legal proceedings, see Note 8 – Debt and Note 10 – Commitments and Contingencies 9 to the accompanying unaudited condensed consolidated financial statements, which are incorporated herein by reference.

### Item 1A. Risk Factors.

There have been no material changes from the risk factors disclosed under “Risk Factors” in Part I, Item 1A of our 2023 Annual Report. The risks and uncertainties described in our 2023 Annual Report are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also materially adversely affect our business, financial condition or results of operations.

### Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

### Item 3. Defaults Upon Senior Securities.

None.

### Item 4. Mine Safety Disclosures.

None.

### Item 5. Other Information.

#### *Executive Compensation*

On August 13, 2024, the Company entered into an amended and restated executive employment agreement (the “Employment Agreement”) with Rajiv Shukla, the Executive Chairman of the Board which is effective as of July 30, 2024 (the “Effective Date”). Mr. Shukla will receive, starting with calendar year 2024, a base salary at an annualized rate of \$360,000 (the “Base Salary”) inclusive of base salary paid prior to the date of the Employment Agreement, which may be adjusted from time to time by the Compensation Committee of the Board (“Compensation Committee”). In addition, any fully vested shares of Common Stock granted to Mr. Shukla under his executive employment agreement, dated December 29, 2023 (the “Original Employment Agreement”), as part of his annual base compensation was cancelled as of the Effective Date. Nothing in the Employment Agreement will amend, revoke or otherwise change anything related to Mr. Shukla’s outstanding stock options granted prior to the date of the Employment Agreement.

In addition, Mr. Shukla has the opportunity to earn an annual bonus with a target amount of 50% of his Base Salary in effect at the end of the applicable year. The amount of such annual bonus will be solely determined by the Compensation Committee based on the satisfactory achievement of corporate and/or personal objectives set by the Compensation Committee.

The Employment Agreement also provides Mr. Shukla the opportunity to receive restricted stock units with respect to the Common Stock (“RSUs”) upon the achievement of the milestones detailed in (a) and (b) below, subject to continued employment through the applicable grant date. All RSUs awarded will vest immediately upon achievement of the milestone described below and will provide for share withholding or a broker-assisted share sale to cover any withholding taxes due upon the vesting of the RSUs.

- a) Upon the initial achievement of at least \$5 million in net revenue for any trailing 12-month period subsequent to April 1, 2024, a number of RSUs eq

2% of the Company's net revenue (e.g. if \$5 million in revenue is achieved, the number of RSUs that vest would be 100,000); and

- b) Upon the initial achievement of at least \$10 million in net revenue for any trailing 12-month period subsequent to April 1, 2024, an additional number of RSUs equal to 3.5% of the Company's net revenue in excess of \$5 million (e.g. if \$10 million in revenue is achieved, the number of RSUs awarded would be 175,000).

Under the Employment Agreement, Mr. Shukla also has the opportunity to receive cash compensation for the achievement of the following performance milestones subject to continued employment through the applicable closing date:

33

- a) Upon the closing of an acquisition of the Company for an aggregate purchase price of between \$150 million and \$250 million during the 24-month period ending April 1, 2026, Mr. Shukla would receive cash incentive compensation of \$5 million;
- b) Upon the closing of an acquisition of the Company for an aggregate purchase price of between \$250 million and \$325 million during the 24-month period ending April 1, 2026, Mr. Shukla would receive cash incentive compensation of \$10 million; or
- c) Upon the closing of an acquisition of the Company for an aggregate purchase price equal to or more than \$325 million during the 24-month period ending April 1, 2026, Mr. Shukla would receive cash incentive compensation of \$15 million.

If Mr. Shukla is terminated by the Company without "cause" or upon Mr. Shukla's resignation for "good reason" (each as defined in the Employment Agreement), the Company will pay to him, in addition to any unpaid portion of Mr. Shukla's Base Salary or unpaid portion of any annual bonus that would have been earned with respect to the fiscal year ended immediately prior to such termination, (a) a pro rata bonus for the year of termination, (b) 12 months Base Salary, and (c) 12 months of COBRA coverage. If such termination occurs within three months preceding or 15 months following a "change in control" (as defined in the Employment Agreement), (a) the Company will pay to Mr. Shukla, in addition to the unpaid portion of any annual bonus that would have been earned with respect to the fiscal year ended immediately prior to such termination, (i) a pro rata bonus for the year of termination, (ii) 18 months Base Salary, (iii) 18 months of COBRA coverage, and (b) all outstanding time-based equity awards of Mr. Shukla will accelerate and vest upon the later of such termination and the change in control.

If Mr. Shukla is terminated by the Company due to death or "disability" (as defined in the Employment Agreement), the Company will pay to him a pro rata bonus for the year of termination. The foregoing severance payments and benefits are subject to Mr. Shukla executing and not revoking a general release of claims against the Company and its affiliates.

The foregoing description of the terms of the Employment Agreement does not purport to be complete and is qualified in its entirety by reference to full text of the Employment Agreement, a copy of which is filed as Exhibit 10.1 hereto and is incorporated by reference herein.

#### Insider Trading Arrangements

During the three months ended **March 31, 2024** ~~June 30, 2024~~, none of the Company's directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted, terminated or modified a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).

3034

#### Item 6. Exhibits.

Furnish the exhibits required by Item 601 of Regulation S-K (§ 229.601 of this chapter).

Number	Description
10.1† 10.1*	<a href="#">Membership Interest Amended and Restated Executive Employment Agreement between Carmell Corporation and Rajiv Shukla, dated August 10, 2024.</a>

10.2	<a href="#">Form of Securities Purchase Agreement effective March 20, 2024, by and among Carmell Corporation, Axolotl Biologix, LLC, Burns Ventures, LLC, H. Rodney Burns, AXO XP, LLC, and Protein Genomics, LLC (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on March 26, 2024 April 4, 2024).</a>
10.3	<a href="#">Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed with the SEC on April 4, 2024).</a>
31.1*	<a href="#">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>
31.2*	<a href="#">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>
32.1*	<a href="#">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>
32.2*	<a href="#">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>
101.INS	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.
101.SCH	Inline XBRL Taxonomy Extension Schema <b>With</b> with Embedded Linkbase Documents
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

\* Filed herewith

† Annexes, schedules and exhibits to this Exhibit omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.

31 35

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

### Carmell Corporation

Date: **May 15, 2024** August 14, 2024

By: /s/ Rajiv Shukla

Name: Rajiv Shukla

Title: **Chief Executive Officer and** Executive Chairman

### Carmell Corporation

Date: **May 15, 2024** August 14, 2024

By: /s/ Bryan J. Cassaday

Name: Bryan J. Cassaday

Title: Chief Financial Officer

32 36

---

## AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT

This Amended and Restated Executive Employment Agreement (the "Agreement"), dated August 13, 2024, is made and entered into by and between Carmell Corporation, a Delaware corporation (the "Company") and Rajiv Shukla (the "Executive") and will be deemed effective as of July 30, 2024 (the "Effective Date"), each of the Company and the Executive, a "party" and together, the "parties."

### Introduction

WHEREAS, the Executive is currently employed by the Company as its Executive Chairman;

WHEREAS, the Company and the Executive entered into an Executive Employment Agreement, dated December 29, 2023 (the "Prior Agreement"); and

WHEREAS, the parties desire to amend and restate the Prior Agreement, as of the Effective Date.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the parties hereby agree as follows:

- 1. Position.** The Executive will continue to serve as the Executive Chairman of the Company and will report to the board of directors of the Company (the "Board"). In addition to performing the duties and responsibilities associated with that position, from time to time, the Board may assign to the Executive other duties and responsibilities reasonable and consistent with such position. Subject to the list of pre-approved activities in which the Executive may engage as set forth as Exhibit A hereto, which shall be updated from time to time to reflect any additional activities consented to by the Board subsequent to the Effective Date, if any, the Executive agrees to perform his duties in furtherance of the Company's interests. The Executive also agrees that during his employment with the Company, he will not engage in any other employment, consulting or business services without the written consent of the Board; provided, however, that without such consent, the Executive may engage in charitable or public service, including serving on up to a maximum of three (3) boards. Compensation received by the Executive in connection with any outside activities shall be the exclusive property of the Executive.
- 2. Term.** The Executive's employment pursuant to this Agreement will continue until terminated in accordance with Section 11 hereof.
- 3. Place of Performance.** The Executive may work remotely from his residence in Florida, provided, however, that the Executive understands and agrees that he may be required to travel from time to time for business purposes.
- 4. Compensation.** This is a full-time, exempt position. Starting with calendar year 2024, the Company will pay the Executive base salary at an annualized rate of \$360,000 ("Base Salary") inclusive of base salary paid prior to the date of this Agreement, which shall be reviewed on an annual basis by the Compensation Committee of the Board (the "Committee") and may be adjusted from time to time by the Committee. All cash compensation will be payable in accordance with the Company's standard payroll schedule and subject to applicable deductions and withholdings. In addition, any equity award granted to the Executive under the Prior Agreement as Total Annual Compensation, as defined in such agreement, is hereby canceled as of the Effective Date.
- 5. Annual Bonus.** For each calendar year ending during his employment, the Executive will have the opportunity to earn an annual bonus with a target amount of 50% of the Base Salary in effect at the end of the applicable year (the "Target Bonus"). The actual bonus payable to the Executive, if any, with respect to any year may be more or less than the Target Bonus and will be determined by the Committee, in its sole discretion, based on the satisfactory achievement of corporate and/or personal objectives established by the Committee. Except as otherwise provided herein or determined by the Committee, payment of any Earned Bonus (as defined in Section 15 below) will be paid no later than March 15 of the year following the year to which the Earned Bonus relates and will be conditioned on the Executive's continued service through the date that annual bonuses are paid to the Company's executive officers generally with respect to the applicable year.

**6. Performance Milestone Equity Incentives.** The Executive may be granted restricted stock units with respect to the Company's common stock ("RSUs") upon the achievement of the milestones detailed in (a) and (b) below, subject to continued employment through the applicable grant date. All RSUs awarded pursuant to this Section 6 will vest immediately upon grant, to the extent described below and subject to continued employment through the applicable grant date, and will provide for share withholding or a broker-assisted share sale to cover any withholding taxes due upon the vesting of the RSUs.

- (a) Upon the initial achievement of at least \$5 million in net revenue for any trailing 12-month period subsequent to April 1, 2024, a number of RSUs equal to 2% of the Company's net revenue (e.g. if \$5 million in revenue is achieved, the number of RSUs that vest would be 100,000); and
- (b) Upon the initial achievement of at least \$10 million in net revenue for any trailing 12-month period subsequent to April 1, 2024, an additional number of RSUs equal to 3.5% of the Company's net revenue in excess of \$5 million (e.g. if \$10 million in revenue is achieved, the number of RSUs awarded would be 175,000).

**7. Performance Milestone Cash Incentives.** The Executive may receive cash compensation for the achievement of the following performance milestones subject to continued employment through the applicable closing date:

- (a) Upon the closing of an acquisition of the Company for an aggregate purchase price of between \$150 million and \$250 million during the 24-month period ending April 1, 2026, the Executive will receive cash incentive compensation of \$5 million;
- (b) Upon the closing of an acquisition of the Company for an aggregate purchase price of between \$250 million and \$325 million during the 24-month period ending April 1, 2026, the Executive will receive cash incentive compensation of \$10 million; or
- (c) Upon the closing of an acquisition of the Company for an aggregate purchase price equal to or more than \$325 million during the 24-month period ending April 1, 2026, the Executive will receive a cash incentive compensation of \$15 million.

**8. Stock Options.** On October 9, 2023, the Executive was granted options to purchase 426,878 shares of Common Stock with an exercise price equal to the closing market price as of the date of such grant, subject to the terms of the Carmell Corporation 2023 Long-Term Incentive Plan and the form of stock option agreement thereunder. On July 26, 2024, the Executive was granted options to purchase 450,000 shares of Common Stock with an exercise price equal to the closing market price as of the date of such grant, subject to the terms of the Carmell Corporation 2023 Long-Term Incentive Plan and the form of stock option agreement thereunder. The Executive may receive additional equity awards at times and on terms determined by the Committee in its discretion. Nothing set forth in this Agreement shall amend, revoke or otherwise change anything related to the Executive's existing outstanding stock option awards made prior to the date of the Agreement.

**9. Benefits; Business Expenses.**

- (a) The Executive shall be entitled to participate in Company benefit plans that are generally available to other employees of the Company of similar rank and tenure, in accordance with and subject to the terms and conditions of such plans, as in effect from time to time.
- (b) The Company will pay or reimburse the Executive for all reasonable business expenses incurred or paid by the Executive in the performance of his duties and responsibilities for the Company in accordance with the expense reimbursement policies of the Company, as may be amended from time to time.

**10. Restrictive Covenants Agreement.** The Executive acknowledges that the Restrictive Covenants Agreement attached hereto as Exhibit B (the "Restrictive Covenants Agreement") remains in effect.

**11. Termination.**

- (a) The Executive's employment hereunder is at-will and can be terminated at any time by the Executive or the Company for any reason or no reason. The Executive's employment shall terminate on the earliest

---

of: (i) on the date set forth in a written notice to the Executive from the Board that the Executive's employment with the Company has been or will be terminated, (ii) on the date not less than 30 days following written notice from the Executive to the Company that the Executive is resigning from the Company, (iii) on the date of the Executive's death, or (iv) on the date set forth in a written notice to the Executive from the Board that the Executive's employment is terminated on account of the Executive's Disability, as determined by the Board. Notwithstanding the foregoing, in the event that the Executive gives notice of termination to the Company, the Company may unilaterally accelerate the date of termination, and such acceleration shall not constitute a termination by the Company for purposes of this Agreement.

- (b) Upon cessation of the Executive's employment for any reason, unless otherwise consented to in writing by the Board, the Executive will resign immediately from any and all officer, director and other positions the Executive then holds with the Company and its affiliates and agrees to execute such documents:

may be requested by the Company to confirm that resignation.

- (c) Upon any cessation of the Executive's employment with the Company, the Executive will be entitled only to such compensation and benefits as described Section 12 below.
- (d) The Executive agrees that, following any cessation of his employment and subject to reimbursement of his reasonable expenses, he will cooperate with the Company and its counsel with respect to any matter (including litigation, investigations, or governmental proceedings) in which the Executive was in any way involved during his employment with the Company. The Executive agrees to render such cooperation in a timely manner on reasonable notice from the Company, provided the Company exercises reasonable efforts to limit and schedule the need for the Executive's cooperation so as not to materially interfere with his other professional obligations.
- (e) The Executive agrees that, upon any cessation of his employment, he will deliver to the Company (and will not retain in his possession or control, or deliver to anyone else) all property and equipment of the Company, including without limitation (i) all keys, books, records, computer hardware, software, cellphones, access cards, credit cards and identification, and (ii) all other Company materials (including copies thereof), including without limitation all records, data, notes, reports, proposals, lists or correspondence.

## **12. Rights Upon Termination.**

- (a) **Termination without Cause.** If the Executive's employment by the Company ceases due to a termination by the Company without Cause (as defined below) or resignation by the Executive for Good Reason other than during a Protected Period:
  - (i) the Company shall pay to the Executive the Accrued Obligations (as defined below) at the time such Accrued Obligations would otherwise be paid according to the Company's usual payroll practices;
  - (ii) to the extent then unpaid, the Company shall pay to the Executive the Earned Bonus (as defined below);
  - (iii) the Company shall pay to the Executive the Pro Rata Bonus (as defined below);
  - (iv) the Company shall make monthly cash severance payments equal to one-twelfth of the Executive's Base Salary as in effect immediately prior to the cessation of employment for a period equal to the Severance Period; and
  - (v) if the Executive is eligible for, and validly elects to receive, continuation coverage under the Company's group health plan (if any) pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA"), the Company shall pay or reimburse the applicable premium otherwise payable for COBRA continuation coverage for the Executive and his eligible dependents, to the extent such premium exceeds the monthly amount charge for active similarly-situated employees of the Company for the same coverage until the earlier of (x) the end of the Severance Period, or (y) such date as the Executive becomes eligible for group health insurance through another employer, to the extent doing so would (i) not give rise to an excise tax under applicable laws and (ii) is otherwise permitted under applicable laws.
- (b) **Termination during Protected Period.** If the Executive's employment by the Company ceases due to a

---

termination by the Company without Cause or a resignation by the Executive for Good Reason (as defined below), and in each case, if such cessation of employment occurs during a Protected Period (as defined below), then in addition to the benefits and payments described in Sections 12(a)(ii)- 12(a)(v) (increased as applicable for the longer Severance Period for a termination during the Protected Period) all outstanding equity awards that are subject to vesting based solely on the passage of time and the Executive's continued employment shall become vested upon the later of the date of the Executive's cessation of employment and the first Change in Control that occurs during the Protected Period.

- (c) **Other Terminations.** If the Executive's employment with the Company ceases for any reason other than as described in Sections 12(a) and 12(b) above (including but not limited to (i) termination by the Company for Cause, (ii) resignation by the Executive other than for Good Reason, (iii) termination as a result of the Executive's Disability, or (iv) the Executive's death), then the Company's obligation to the Executive will be limited solely to the payment of the Accrued Obligations through the date of such cessation of employment; provided, however, that in the event of the Executive's death or Disability, the Company's obligation shall also include the Earned Bonus and the Pro Rata Bonus. The Accrued Obligations shall be paid on the first payroll date following the last date of employment to the extent administratively feasible and, if not, then on the second payroll date following the last date of employment. The foregoing will not be construed to limit the Executive's right to payment or reimbursement for claims incurred prior to the date of such termination under any insurance contract funding an employee benefit plan, policy or arrangement of the Company in accordance with the terms of such insurance contract.
- (d) **Other Provisions Related to Severance Benefits.**
  - (i) Except as otherwise provided in Sections 12(a)-(b) or pursuant to COBRA, all compensation and benefits will cease at the time of the Executive's

cessation of employment, and the Company will have no further liability or obligation by reason of such cessation of employment.

- (ii) The payments and benefits described in Sections 12(a)-(b) are in lieu of, and not in addition to, any other severance arrangement maintained by Company.
- (iii) Notwithstanding any provision of this Agreement, the payments and benefits described in Sections 12(a)(ii)- 12(a)(v) and Section 12(b) are conditional on the Executive's execution and delivery to the Company and the expiration of all applicable statutory revocation periods, by the 60th day following effective date of the Executive's cessation of employment, of a general release of claims against the Company and its affiliates in a form and manner satisfactory to the Company (the "Release") and on the Executive's continued compliance with the provisions of the Restrictive Covenants Agreement.
- (iv) Subject to Section 13 below (to the extent applicable) and provided the Release requirement described above has been timely satisfied: (w) the Earnout Bonus under Section 12(a)(ii) will be paid on the later of the sixty-fifth (65th) day following the Executive's cessation of employment (the "Settlement Date") or the date such annual bonus would have otherwise been paid, absent the Executive's cessation of employment; (x) the Pro Rata Bonus under Section 12(a)(iii) will be paid on the date such annual bonus would have otherwise been paid, absent the Executive's cessation of employment; and (y) the salary continuation and COBRA premium payments described in Sections 12(a)(iv)- 12(a)(v) and Section 12(b) will commence to be paid on Settlement Date, provided that (A) the initial payment will include any payments that, but for the above-described timing rule, would have otherwise been paid since the date of the Executive's cessation of employment, and (B) in case of a termination under Section 12(b), the benefit described in Section 12(a)(iv) will be paid in a single lump sum on the Settlement Date rather than as monthly severance payments. Notwithstanding the foregoing, if termination of employment under Section 12(b) occurs during the portion of the Protected Period that is before the date of a Change in Control, the salary continuation payments will commence under Section 12(a)(iv) as described above on the Settlement Date, and the lump sum payment of additional amount in accordance with Section 12(b) and clause (B) above will be made as soon as administratively practicable (not more than ten days) after the date of the Change in Control, reduced by any amounts paid in accordance with Section 12(a)(iv) before that date in order to avoid duplication of benefits.

### **13. Section 409A.**

- (a) The parties intend for this Agreement to comply with or be exempt from Section 409A of the Code, and all provisions of this Agreement will be interpreted and applied accordingly. Nonetheless, the Company does not guarantee the tax treatment of any compensation payable to the Executive.
- (b) Notwithstanding anything to the contrary in this Agreement, no portion of the benefits or payments to be made under Section 12(a) or Section 12(b) above will be payable until the Executive has a "separation from service" from the Company within the meaning of Section 409A of the Code. In addition, to the extent compliance with the requirements of Treas. Reg. § 1.409A-3(i)(2) (or any successor provision) is necessary to avoid the application of an additional tax under Section 409A of the Code to payments due to the Executive upon or following his "separation from service," then notwithstanding any other provision of this Agreement (or any otherwise applicable plan, policy, agreement or arrangement), any such payments that are otherwise due within six months following the Executive's "separation from service" (taking into account the preceding sentence of this paragraph) will be deferred without interest and paid to the Executive in a lump sum immediately following that six month period. This paragraph should not be construed to prevent the application of Treas. Reg. § 1.409A-1(b)(9)(iii) (or any successor provision) to amounts payable hereunder. For purposes of the application of Section 409A of the Code, each payment in a series of payments will be deemed a separate payment.
- (c) Notwithstanding anything in this Agreement to the contrary, to the extent an expense, reimbursement or in-kind benefit provided to the Executive pursuant to this Agreement or otherwise constitutes a "deferral of compensation" within the meaning of Section 409A of the Code: (i) the amount of expenses eligible for reimbursement or in-kind benefits provided to the Executive during any calendar year will not affect the amount of expenses eligible for reimbursement or in-kind benefits provided to the Executive in any other calendar year, (ii) the reimbursements for expenses for which the Executive is entitled to be reimbursed shall be made on or before the last day of the calendar year following the calendar year in which the applicable expense is incurred, and (iii) the right to payment or reimbursement or in-kind benefits hereunder may not be liquidated or exchanged for any other benefit.

### **14. Section 280G.**

- (a) Notwithstanding any contrary provision of this Agreement (or any plan, policy, agreement or other arrangement covering the Executive), if any payment, right or benefit paid, provided or due to the Executive, whether pursuant to this Agreement or otherwise (each, a "Payment," and collectively, the "Total Payments"), would subject the Executive to the excise tax imposed by Section 4999 of the Code (the "Excise Tax"), then the Total Payments will be reduced to the minimum extent necessary to avoid the imposition of the Excise Tax, but only if (i) the amount of such Total Payments, as so reduced, is greater than or equal to (ii) the amount of such Total Payments without reduction (in each case, determined on an after-tax basis). Any reduction of the Total Payments required by this paragraph will be implemented by determining the Parachute Ratio (as defined below) for each Payment and then by reducing the Total Payments in order, beginning with the Payment with the highest Parachute Ratio. For Payments with the same Parachute Ratio, later Payments will be

reduced before earlier Payments. For Payments with the same Parachute Ratio and the same time of payment, each Payment will be reduced proportionately. For purposes of this paragraph, "Parachute Ratio" means a fraction, (x) the numerator of which is the value of the applicable Payment, as calculated for purposes of Section 280G of the Code, and (y) the denominator of which is the economic value of the applicable Payment.

- (b) All determinations required to be made under this Section *b* including whether and when an adjustment to any Payments is required and, if applicable, which Payments are to be so adjusted, shall be made by an independent accounting firm selected by the Company from among the four (4) largest accounting firms in the United States or any nationally recognized financial planning and benefits consulting company (the "Accounting Firm") which shall provide detailed supporting calculations both to the Company and to the Executive within fifteen (15) business days of the receipt of notice from the Company or the Executive that there has been or will be a Payment, or such earlier time as is requested by the Company or the Executive. In the event that the Accounting Firm is serving as accountant or auditor for the individual, entity or group effecting the "change in control of the Company" (within the meaning of Sections 280G and 4999 of the Code) to which the Payments relate, the Company shall appoint another nationally recognized accounting firm to make the determinations required hereunder (which accounting

---

firm shall then be referred to as the Accounting Firm hereunder). All fees and expenses of the Accounting Firm shall be borne solely by the Company. If the Accounting Firm determines that no Excise Tax is payable by the Executive, it shall furnish the Executive with a written opinion that failure to report the Excise Tax on the Executive's applicable federal income tax return would not result in the imposition of a negligence or similar penalty. Any determination by the Accounting Firm shall be binding upon the Company and the Executive.

**15. Certain Definitions.** For purposes of this Agreement:

- (a) "Accrued Obligations" mean any portion of the Executive's Base Salary payable for the payroll period in which the Executive's termination of employment occurs for service prior to the termination date and any business expenses properly incurred but not yet reimbursed, as provided for in Section 9(B). Accrued Obligations also include any incentives earned under Section 6 and Section 7, to the extent unpaid.
- (b) "Cause" means (i) the Executive's refusal to comply with any lawful directive or policy of the Company and which is of the type consistent with the Executive's positions within the Company, which refusal is not cured by the Executive within ten (10) days of such written notice from the Company; (ii) the Company's determination that the Executive has committed any act of dishonesty, embezzlement, unauthorized use or disclosure of confidential information or other intellectual property or trade secrets, common law fraud or other fraud against the Company or any subsidiary or affiliate; (iii) a material breach of the Executive of any written agreement with or any fiduciary duty owed to any Company or any subsidiary or affiliate; (iv) the Executive's commission of felony or any misdemeanor involving material dishonesty or moral turpitude; or (v) the Executive's habitual or repeated misuse of, or habitual or repeated performance of the Executive's duties under the influence of, alcohol, illegally obtained prescription controlled substances or non-prescription controlled substances.
- (c) "Change in Control" will have the meaning set forth in the Carmell Corporation 2023 Long-Term Incentive Plan, as may be amended from time to time.
- (d) "Code" means the Internal Revenue Code of 1986, as amended.
- (e) "Disability" means a condition entitling the Executive to benefits under the Company's long-term disability plan, policy or arrangement; provided, however, that if no such plan, policy or arrangement is then maintained by the Company and applicable to the Executive, "Disability" will mean illness, incapacity or mental or physical condition that renders the Executive unable or incompetent, with or without a reasonable accommodation, to carry out the job responsibilities that the Executive held or the tasks that the Executive was assigned at the time the disability commenced, as determined in good faith by a physician mutually acceptable to the Company and the Executive, for a period of 90 consecutive days, or 180 non-consecutive days in any rolling 12-month period. Termination as a result of a Disability will not be construed as a termination by the Company "without Cause."
- (f) "Earned Bonus" means the bonus amount (if any) that would have been earned under Section 5 with respect to the fiscal year ended immediately prior to the cessation of the Executive's employment, but for such cessation, to the extent unpaid.
- (g) "Good Reason" means: (i) a reduction in the Base Salary, as then in effect, other than in connection with the same percentage across-the-board decrease in base salaries applicable to other key executives; or (ii) the Company's material breach of this Agreement, provided, however, that no such event will constitute Good Reason unless (x) the Executive, within 60 days after the initial existence of the act or failure to act by the Company that constitutes "Good Reason" within the meaning of this Agreement, provides the Company with written notice that describes, in particular detail, the act or failure to act that the Executive believes to constitute "Good Reason" and identifies the particular clause of this Section 15(g) that the Executive contends is applicable to such act or failure to act; (y) the Company, within 30 days after its receipt of such notice, fails or refuses to rescind such act or remedy such failure to act so as to eliminate "Good Reason" for the termination by the Executive of the Executive's employment relationship with the Company; and (z) the Executive resigns from the employ of the Company on or before that date that is 12 months after the initial existence of the act or failure to act by the Company that constitutes

“Good Reason.” If the requirements of the immediately preceding sentence are not fully satisfied on a timely basis, then the resignation by the Executive from the employ of the Company shall

---

not be deemed to have been for “Good Reason,” and the Executive shall not be entitled to any of the benefits to which the Executive would have been entitled if the Executive had resigned from the employ of the Company for “Good Reason,” and the Company shall not be required to pay any amount or provide any benefit that would otherwise have been due to the Executive under this Agreement had the Executive resigned with “Good Reason.”

(h) “Pro Rata Bonus” means the bonus amount (if any) that would have been earned under Section 5 with respect to the fiscal year of the Executive’s cessation of employment had such cessation not occurred based on actual performance results, prorated based on (i) the number of days in such fiscal year through the date of such termination of employment, divided by (ii) the total number of days in such fiscal year.

(i) “Protected Period” means the eighteen (18) month period that begins on the date that is three (3) months prior to the date of a Change in Control.

(j) “Severance Period” means twelve (12) months. Notwithstanding the foregoing, with respect to a cessation of employment due to a termination by the Company without Cause or resignation by the Executive for Good Reason that occurs (in either case) during the Protected Period, “Severance Period” shall mean eighteen (18) months.

**16. Company Policies.** The Executive will comply with all policies of the Company in effect from time to time, including (without limitation) policies regarding ethics, personal conduct, stock ownership, securities trading, clawback and hedging and pledging of securities.

**17. Indemnification.** In addition to any rights to indemnification to which the Executive may be entitled under the Company’s governing documents, the Company shall obtain and maintain an appropriate level of Directors and Officers Liability insurance coverage for the Executive’s benefit on the same terms as applicable to other directors and C-level the Executives of the Company.

**18. Confidential Information.**

(a) During the Executive’s employment and at all times following the termination of the Executive’s employment for any reason, the Executive shall not, without the prior written consent of the Company, use, divulge, disclose or make accessible to any other person, firm, partnership, corporation or other entity any confidential or proprietary information pertaining to the business of the Company, including, without limitation, know-how; trade secrets; customer list pricing policies; operational methods; and other information relating to products, processes, past, current and prospective customers or other third party services and other business and financial affairs (collectively, the “Confidential Information”), in each case to which the Executive has had or may have access or which the Executive developed or may have developed. Notwithstanding anything in this Agreement or any other Company document to the contrary, the Executive shall be permitted, and the Company acknowledges the Executive’s right, to divulge, disclose, or make accessible to the Executive’s counsel any Confidential Information that, in the good faith judgment of the Executive (or the Executive’s counsel), is necessary or appropriate in order for counsel to evaluate the Executive’s rights, duties or obligations under this Agreement or in connection with the Executive’s status as an officer and/or director of the Company.

(b) In the event that the Executive receives a request or is required to disclose all or any part of the Confidential Information to a third party (other than the Executive’s counsel), the Executive agrees to (a) promptly notify the Company in writing of the existence, terms and circumstances surrounding such request or requirement; (b) consult with the Company, at the Company’s request, on the advisability of taking legally available steps to restrict or narrow such request or requirement; and (c) assist the Company, at the Company’s request and expense, in seeking a protective order or other appropriate remedy. In the event that such assistance from the Executive pursuant to this provision or otherwise waives compliance with the provisions hereof, the Executive shall not be liable for such disclosure unless such disclosure was caused by or resulted from a previous disclosure by the Executive not permitted by this Agreement. Further, nothing in this Agreement or any other agreement by and between the Company and the Executive shall prohibit the Executive from voluntarily communicating with an attorney retained by the Executive, (ii) voluntarily communicating with any law enforcement, government agency including the Security and Exchange Commission (“SEC”), Equal Employment Opportunity Commission or a state or local commission on human rights, any self-regulatory organization, regarding possible

violations of law, including criminal conduct and unlawful employment practices or (iii) recovering a SEC whistleblower award as provided under Section 21F of the Securities Exchange Act of 1934, in each case without advance notice to the Company.

(c) Pursuant to 18 U.S.C. §1833(b), the Executive acknowledges that the Executive shall not have criminal or civil liability under any Federal or State trade secret law for the disclosure of a trade secret of the Company that (i) is made (A) in confidence to a Federal, State, or local government official, either directly or indirectly, or to the Executive's attorney; and (B) solely for the purpose of reporting or investigating a suspected violation of law; or (ii) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. If the Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, the Executive may disclose the trade secret to his attorney and use the trade secret information in that court proceeding if the Executive (i) files any document containing the trade secret under seal, and (ii) does not disclose the trade secret, except pursuant to a court order. Nothing in this Agreement is intended to conflict with 18 U.S.C. §1833(b) or create liability for disclosures of trade secrets that are expressly allowed by such section.

**19. No Conflicting Agreements.** The Executive represents and warrants that he is not a party to or otherwise bound by any agreement or restriction that could conflict with, or be violated by, the performance of his duties to the Company or his obligations under this Agreement. The Executive will not use or misappropriate any intellectual property, trade secrets or confidential information belonging to any third party.

**20. Taxes.** All compensation payable to the Executive is subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law. The Executive hereby acknowledges that the Company does not have a duty to design its compensation policies in a manner that minimizes the Executive's tax liabilities, and the Executive may not make any claim against the Company or its Board related to tax liabilities arising from his compensation.

**21. Entire Agreement; Assignment; Amendment.**

(a) This Agreement, together with the Restrictive Covenants Agreement, constitutes the final and entire agreement of the parties with respect to the matters covered hereby and replaces and supersedes all prior agreements, discussions, negotiations, representations or understandings (whether written, oral or implied) relating to the Executive's employment by the Company, including without limitation the Prior Agreement.

(b) The rights and obligations of the Executive hereunder are personal and may not be assigned. The Company may assign this Agreement, and its rights and obligations hereunder, to any entity to which the Company transfers substantially all of its assets (or an affiliate thereof). Notwithstanding any other provision of this Agreement, any such assignment of this Agreement by the Company will not entitle the Executive to severance benefits under Sections 12(a), 12(b) or otherwise, whether or not the Executive accepts employment with the assignee. No provision of this Agreement may be amended or modified unless such amendment or modification is agreed to in writing and signed by the Executive and duly authorized representative of the Company's Board of Directors. No waiver by either of the parties of any breach by the other party hereto of any condition or provision of this Agreement to be performed by the other party hereto shall be deemed a waiver of any similar or dissimilar provision or condition at the same or any prior or subsequent time, nor shall the failure of or delay by either of the parties in exercising any right, power, or privilege hereunder operate as a waiver thereof to preclude any other or further exercise thereof or the exercise of any other such right, power, or privilege.

(c) Should any provision of this Agreement be held by a court of competent jurisdiction to be enforceable only if modified, or if any portion of this Agreement shall be held as unenforceable and thus stricken, such holding shall not affect the validity of the remainder of this Agreement, the balance of which shall continue to be binding upon the parties with any such modification to become a part hereof and treated as though originally set forth in this Agreement. The parties further agree that any such court is expressly authorized to modify any such unenforceable provision of this Agreement in lieu of severing such unenforceable provision from this Agreement in its entirety, whether by rewriting the offending provision, deleting any or all of the offending provision, adding additional language to this Agreement, or by making such other modifications as it deems warranted to carry out the intent and agreement of

---

the parties as embodied herein to the maximum extent permitted by law. The parties expressly agree that this Agreement as so modified by the court shall be binding upon and enforceable against each of them. In any event, should one or more of the provisions of this Agreement be held to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provisions hereof, and if such provision or provisions are not modified as provided above, this Agreement shall be construed as if such invalid, illegal, or unenforceable provisions had not been set forth herein.

**22. Governing Law.** This Agreement shall be governed by and construed in accordance with the internal laws of the Commonwealth of Pennsylvania, without regard to its choice of law provisions. Any action or proceeding by either the Executive or the Company to enforce this Agreement shall be brought only in

any state or federal court located in the Commonwealth of Pennsylvania. The parties hereby irrevocably submit to the exclusive jurisdiction of such courts and waive the defense of inconvenient forum to the maintenance of any such action or proceeding in such venue.

- 23. Arbitration.** In the event of any dispute under the provisions of this Agreement or otherwise regarding the Executive's employment or compensation (other than a dispute in which the primary relief sought is an injunction or other equitable remedy, such as an action to enforce compliance with the Restrictive Covenants Agreement, the parties shall be required to have the dispute, controversy or claim settled by arbitration in Pittsburgh, Pennsylvania, in accordance with the National Rules for the Resolution of Employment Disputes then in effect of the American Arbitration Association ("AAA"), by one arbitrator mutually agreed upon by the parties (or, if no agreement can be reached within 30 days after names of potential arbitrators have been proposed by the AAA, then by one arbitrator having relevant experience who is chosen by the AAA). Any award or finding will be confidential. The arbitrator may not award attorneys' fees to either party unless a statute or contract at issue specifically authorizes such an award. Any award entered by the arbitrators will be final, binding and non-appealable and judgment may be entered thereon by either party in accordance with applicable law in any court of competent jurisdiction. This arbitration provision will be specifically enforceable. The Company shall pay all costs and expenses unique to arbitration, including without limitation, the arbitrator's fees. Subject to the foregoing, each party will pay for its own costs and attorneys' fees.
- 24. Headings.** The headings of the sections of this Agreement are inserted for convenience only and shall not the meaning of this Agreement.
- 25. Notices.** All notices, demands or other communications hereunder shall be in writing and shall be deemed to have been duly given if delivered in person, by e-mail or fax, by United States mail, certified or registered with return receipt requested, or by a nationally recognized overnight courier service, or otherwise actually delivered: (a) if to the Executive, at the most recent address contained in the Company's personnel files; (b) if to the Company, to the attention of its Legal Department at the address of its principal executive office; or (c) or at such other address as may have been furnished by such person in writing to the other party. Any such notice, demand or communication shall be deemed given on the date given, if delivered in person, e-mailed or faxed, on the date received, if given by registered or certified mail, return receipt requested or overnight delivery service, or three days after the date mailed, if otherwise given by first class mail, postage prepaid.
- 26. Notification to New Employer.** When the Executive's employment with the Company terminates, the Executive agrees to notify any subsequent employer of the restrictive covenants sections contained in this Agreement. In addition, the Executive authorizes the Company to provide a copy of the restrictive covenants sections of this Agreement to third parties, including but not limited to the Executive's subsequent employer.
- 27. Survival.** Upon the expiration or other termination of this Agreement, the respective rights and obligations of the parties hereto shall survive such expiration or other termination to the extent necessary to carry out the intentions of the parties under this Agreement.
- 28. Counterparts.** This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which, taken together, will constitute one and the same

---

Agreement.

- 29. Acknowledgment of Full Understanding.** THE EXECUTIVE ACKNOWLEDGES AND AGREES THAT HE HAS FULLY READ, UNDERSTANDS AND VOLUNTARILY ENTERS INTO THIS AGREEMENT. THE EXECUTIVE ACKNOWLEDGES AND AGREES THAT HE HAS HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT WITH AN ATTORNEY OF HIS CHOICE BEFORE SIGNING THIS AGREEMENT.

[Signature page follows.]

This Agreement has been executed and delivered on the date first above written.

**Carmell Corporation**

By:  
Name: Kathryn Gregory  
Title: Independent Director

**Executive**

By:  
Name: Rajiv Shukla  
Title: Executive Chairman

---

**Exhibit A**

Sole Owner, Constellation Alpha Holdings LLC: holding company for my private investments  
Partner, SPAC Research (owns 33%)

---

**Exhibit 31.1**

**CERTIFICATION PURSUANT TO  
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,  
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Rajiv Shukla, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended **March 31, 2024** ~~June 30, 2024~~ of Carmell Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and I
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that all material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

- (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 15, 2024 August 14, 2024

By: /s/ Rajiv Shukla

Rajiv Shukla

Chief Executive Officer and Executive Chairman

Exhibit 31.2

**CERTIFICATION PURSUANT TO  
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,  
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Bryan J. Cassaday, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 June 30, 2024 of Carmell Corporation ;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and I
- (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that all material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
- (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
- (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
- (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

- (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 15, 2024 August 14, 2024

By: /s/ Bryan J. Cassaday

Bryan J. Cassaday  
Chief Financial Officer

Exhibit 32.1

**CERTIFICATION PURSUANT TO  
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Carmell Corporation (the "Company") on Form 10-Q for the period ending March 31, 2024 June 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 15, 2024 August 14, 2024

By: /s/ Rajiv Shukla

Rajiv Shukla  
Chief Executive Officer and Executive Chairman

Exhibit 32.2

**CERTIFICATION PURSUANT TO  
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Carmell Corporation (the "Company") on Form 10-Q for the period ending March 31, 2024 June 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By: /s/ Bryan J. Cassaday

Date: ~~May 15, 2024~~ August 14, 2024

By: ~~for Bryan J. Cassaday~~

---

Bryan J. Cassaday  
Chief Financial Officer

---

## DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2024, Refinitiv. All rights reserved. Patents Pending.